Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
6-22-2022 10:00 AM

Characterization of galectin-16 expression and function in
placental cells
Jennifer Kaminker, The University of Western Ontario
Supervisor: Alexander Timoshenko, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Biology
© Jennifer Kaminker 2022

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Biology Commons, and the Cell Biology Commons

Recommended Citation
Kaminker, Jennifer, "Characterization of galectin-16 expression and function in placental cells" (2022).
Electronic Thesis and Dissertation Repository. 8628.
https://ir.lib.uwo.ca/etd/8628

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
The processes of cellular differentiation and apoptosis are critical for placental development.
The galectin-16 gene (LGALS16) is associated with these processes in the placenta, but the
mechanism by which it acts is poorly characterized. My bioinformatics analysis revealed that
LGALS16 expression was limited to specific tissues including the placenta and identified
multiple regulatory molecules (transcription factors and miRNAs), which could potentially
control relevant transcriptional and post-transcriptional mechanisms. Considering the
predominant expression of LGALS16 in placenta, I examined the expression, regulation, and
function of LGALS16 in BeWo and JEG-3 cell lines representing in vitro models of trophoblast
differentiation. In both models, LGALS16 was significantly upregulated in parallel with human
chorionic gonadotropin beta (CGB) during trophoblastic differentiation induced by 8-BrcAMP. Inhibition of p38 MAPK and Epac significantly altered LGALS16 expression during
differentiation, while modulation of O-GlcNAc homeostasis failed to change LGALS16 and
CGB expression. Lastly, CRISPR/Cas9 LGALS16 knockouts suppressed expression of CGB.
These findings suggest that LGALS16 may play a role in trophoblastic differentiation through
p38 MAPK and Epac signaling pathways.

Keywords
Galectin-16, LGALS16, placenta, cellular differentiation, O-GlcNAcylation, transcription
factors, cAMP, CRISPR/Cas9 knockout
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Summary for Lay Audience
Galectins are a group of carbohydrate binding proteins with roles in cell growth,
differentiation, and cell death. Of the galectins characterized in humans, galectins-13, -14, and
-16 are highly expressed in the placenta, suggesting that they play a unique role in placental
development. Furthermore, improper expression of these three galectins leads to disorders such
as preeclampsia, a condition characterized by high blood pressure in pregnant mothers that can
be fatal. Limited literature exists on galectin-16 (encoded by the LGALS16 gene) and thus it is
the focus of the current study. Datasets from other studies were extracted and analyzed to
determine the level of galectin-16 in different tissues. This revealed that galectin-16 expression
is expressed at a high level in two tissues, the placenta and brain. I also used a program to align
the upstream sequence of galectin-16 with sequences of binding sites for specific transcription
factors. I determined predicted transcription factors by identifying binding site sequences
which matched with 100% similarity to a part of the upstream sequence. Using placental
culture models, I induced placental differentiation with cAMP and examined the effects on
LGALS16 expression. Additionally, I treated cells with biochemical inhibitors and stimulators
of transcription factors, cAMP signaling molecules, and enzymes responsible for adding and
removing sugars to proteins. I analyzed how these inhibitors/stimulators affected galectin gene
and protein expression, particularly LGALS16, and the biomarker of differentiation, chorionic
gonadotropin. Finally, cell pools were genetically modified to knockout galectin-16 and then
treated with cAMP to test whether cells could still undergo differentiation. In placental cell
models, LGALS16 expression was significantly increased during placental differentiation.
Inhibition of two cAMP signaling molecules led to significant changes in LGALS16 expression
while no changes were observed in response to drugs changing glycosylation of intracellular
proteins. Knocking out galectin-16 in placental cells changed the morphology of cells and
inhibited gene expression of chorionic gonadotropin. These findings provide insights into the
significance of galectin-16 as a critical regulator of placental differentiation which may serve
as a tool to identify dysregulated placental differentiation in cancers and pregnancy disorders.
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Chapter 1

1

Introduction

1.1 Galectins
Galectins are a family of soluble glycan-binding proteins that share a conserved
carbohydrate-recognition domain (CRD) consisting of ~130 amino acids and are
characterized by their affinity for -galactosides. Glycoproteins, proteoglycans and
glycolipids contain glycan groups that can be dynamically exposed as a post-translational
modification in response to various stimuli resulting in “glycosylation signatures”.
Galectins are responsible for decoding the “glycosylation signatures” via Nacetyllactosamine units of glycoproteins and glycolipids to stimulate a signal transduction
cascade. This mechanism allows galectins to play a key role in the regulation of
fundamental biological processes including cell growth, differentiation, migration, death,
and immune responses (Laderach et al., 2010; Timoshenko, 2015).

Galectins exist in all metazoans and are the most widely expressed class of lectins
(Cummings & Liu, 2009). Initially termed an electrolectin, galectins were first discovered
in 1975 in the electric eel (Teichberg et al., 1975). In 1976, galectins were identified in
vertebrates from chick muscle as well as calf heart and lung (de Waard et al., 1976). Studies
have since identified 16 galectin genes in the animal kingdom, 12 of which are expressed
in humans (Timoshenko, 2015). Galectin expression and localization patterns vary in
different cell and tissue types, disease states, and stress responses (Cummings & Liu, 2009;
Johannes et al., 2018; Hong et al., 2021). Moreover, some galectins are abundantly
expressed in a variety of tissues while others are uniquely expressed in a limited number
of tissues suggesting they may have evolved to serve a tissue-specific function (Johannes
et al., 2018).

Three subcategories of galectins have been defined based on domain structure: prototype,
tandem-repeat, and chimeric types (Figure 1) (Timoshenko, 2015). Prototype galectins
contain one CRD and include galectins-1, -2, -5, -7, -10, -11, -13, -14, -15, and -16
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Figure 1. Three structural subcategories of galectins in humans.

Galectins are subcategorized according to their carbohydrate recognition domains (red and
grey). Prototype galectins contain one CRD, tandem-repeat galectins contain two nonidentical CRDs linked by a non-lectin linker domain (blue), and chimera-type contain an
N-terminal end domain (yellow). Adapted figure from (Timoshenko, 2015).
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(Laderach et al., 2010; Timoshenko, 2015) with galectins-13, 14, and -16 sharing over 60%
similarity in their amino acid sequences (Si et al., 2021). Tandem-repeat galectins contain
two homologous CRDs connected by a linker of 70 amino acids and include galectins-4,
-6, -8, -9, and -12 (Laderach et al., 2010). Chimera-type galectins contain one CRD linked
to a non-lectin N terminal proline and glycine rich domain and only includes galectin-3
(Laderach et al., 2010). The CRD forms a -sandwich and contains a conserved galactosebinding site consisting of approximately seven amino acids in addition to non-carbohydrate
binding sites (Johannes et al., 2018). These amino acids next to the galactose-binding site
of the CRD are less conserved and these differences confer varying specificities and
affinities of galectins for longer glycoconjugates (Johannes et al., 2018). These noncarbohydrate binding sites can also lead to dimerization (e.g., galectin-1) (Johannes et al.,
2018). Furthermore, some galectins share homology with the galectin family but do not
bind -galactosides, such as galectin-10 which has a higher affinity for -mannosides, or
may not bind carbohydrates (Cummings & Liu, 2009).

Galectins are synthesized in the cytosol and then widely distributed throughout the cell in
the nucleus, cytoplasm, outer plasma membrane, and extracellular matrix (Johannes,
2018). The localization of galectins plays a key role in governing their function (Vladoiu
et al., 2014). Galectins do not contain a signal sequence for secretion and are found
intracellularly in nuclear, cytoplasmic, or mitochondrial compartments to affect cell growth
and apoptosis (Vladoiu et al., 2014). Extracellular galectins are non-classically secreted
independent of the ER and Golgi via galectin-rich vesicles, exosomes, oligomerisation, and
direct translocation (He & Baum, 2006; Johannes, 2018; Popa et al., 2018). Secreted
galectins can bind to glycan ligands on the cell surface or glycoproteins (i.e. fibronectin
and laminin) in the extracellular matrix to promote cell adhesion and migration (He &
Baum, 2006). Other extracellular galectins bind to cell surface receptors as dimers or
oligomers to facilitate cross-linking and transmembrane signaling (Vladoiu et al., 2014;
Nabi et al., 2015).

Galectins primarily use carbohydrate-independent pathways inside the cell via cytosolic or
nuclear targets as well as carbohydrate-dependent signaling extracellularly to carry out
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their function (Johannes, 2018). However, some extracellular carbohydrate-independent
signaling occurs, while other galectins signal intracellularly through glycan-dependent
mechanisms (Tazhitdinova & Timoshenko, 2020).

1.2 O-GlcNAcylation
O-linked N-acetyl-D-glucosamine (O-GlcNAc) can be added post-translationally to
serine/threonine residues of proteins in a process called O-GlcNAcylation (Figure 2) (Kim
et al., 2017). These modifications may determine the localization of galectins and
ultimately affect their function. The process relies on glucose utilized through the
hexosamine biosynthetic pathway (HBP) (Buse, 2006). This involves the conversion of
fructose-6-phosphate

to

glucosamine-6-phosphate,

glutamine:fructose-6-phosphate

amidotransferase

which

(GFAT)

to

is

catalyzed

generate

by

UDP-N-

acetylglucosamine (UDP-GlcNAc) (Buse, 2006). O-GlcNAc transferase (OGT) uses UDPGlcNAc as a substrate to add O-GlcNAc while O-GlcNAcase (OGA) removes O-GlcNAc
(Yang & Qian, 2017). Therefore, the activity of OGA and OGT affects the level of OGlcNAcylated proteins in a cell (Yang & Qian, 2017).

O-GlcNAcylation levels vary in different cell types and during differentiation.
Undifferentiated stem cells exhibit a high level of O-GlcNAc as transcription factors
important in maintaining pluripotency (i.e. OCT4, GATA-1, SOX2, NANOG, C-MYC,
and KLF4) are O-GlcNAcylated (Jang et al., 2012). HL-60 and HT-29 cells that
differentiate into neutrophils and enterocytes, respectively, display decreased O-GlcNAc
(Sherazi et al., 2018). However, osteogenic (Koyama & Kamemura, 2015), adipocytic
(Ishihara et al., 2010), chondrocytic (Andrés-Bergós et al., 2012), and corneal epithelial
(McColgan et al., 2020) cellular differentiation are associated with an increase in global OGlcNAc. These changes in O-GlcNAcylation during differentiation are linked to the
secretion and accumulation of galectins. For instance, increased galectin secretion was
shown during the differentiation of plasma cells (Tsai et al., 2011), macrophages (Novak
et al., 2012), granulocytes (Barrow et al., 2011), muscle cells (Cooper & Barondes, 1990;
Harrison & Wilson, 1992), and adipocytes (Wang et al., 2004). Additionally, galectin gene
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Figure 2. Diagram of the generation of UDP-GlcNAc in the hexosamine biosynthetic
pathway and O-GlcNAcylation.
UDP-GlcNAc is used as a substrate for O-GlcNAcylation, which is carried out by enzymes
OGT and OGA. OGT adds GlcNAc to serine/threonine residues of proteins and can be
inhibited by AC. OGA removes GlcNAc and can be inhibited by thiamet G (modified from
Kim et al., 2017).
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expression profiles differ when global O-GlcNAcylated levels of proteins are high or low
in cells. A model has been proposed suggesting that stem cells have a high O-GlcNAc level
and an intracellular accumulation of galectins while differentiated cells have a low OGlcNAc level and an increase in galectin secretion (Tazhitdinova & Timoshenko, 2020).
O-GlcNAcylation levels have also been associated with placental development and
pathologies during pregnancy. For example, maternal hyperglycemia is associated with an
increase in O-GlcNAcylation which may affect human fetal development (Ning & Yang,
2021). Moreover, changes in O-GlcNAcylation levels occur in the placentas of mothers
with diabetes which can result in endocytosis of trophoblast cells and altered fetal growth
(Palin et al., 2021). O-GlcNAcylation has also been shown to regulate decidualization,
transcription factors, and maternal stress in the placentas of mice (Lima et al., 2018).

1.3 Placenta
During pregnancy, the placenta is formed as an interface between the mother and fetus and
is responsible for transport, metabolism, protection, and endocrine functions. This
specialized organ is vital for successful embryonic development. The placenta transfers
oxygen and nutrients to the fetus and utilizes these for its own function while it removes
carbon dioxide and waste from the fetus (Gude, 2004). Amino acids and lipids are
metabolized by the placenta and these products are released back into circulation (Gude,
2004). Additionally, the placenta protects the fetus from toxic substances with a variety of
mechanisms, such as export pumps, and transports maternal antibodies to regulate passive
immunity of the fetus (Gude, 2004). Hormones are also produced by the placenta and
released into maternal and fetal circulation (Gude, 2004). These include the glycoprotein,
human chorionic gonadotropin (hCG), and the steroid hormone, progesterone, which are
tightly linked to each other (Gude, 2004). In early pregnancy, syncytiotrophoblasts (STBs)
are the primary producers of hCG to maintain the corpus luteum and promote progesterone
secretion for embryo implantation and growth as well as proper capillary development
(Cole, 2010; Fournier, Guibourdenche, & Evain-Brion, 2015). Progesterone is responsible
for supporting decidualization; inhibiting uterine contraction, menstruation, and labour;
and suppressing immune responses (Cole, 2010; Ku et al., 2018; Peavey et al., 2021). hCG
is a dimer comprised of an  and  subunit (Kardana & Cole, 1994). hCG peaks at 10
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weeks of pregnancy leading to an increase in progesterone (Cole, 2010). However, hCG
decreases in the second and third trimesters which results in a decrease of the luteal
production of progesterone (Cole, 2010). Consequently, trophoblasts become the primary
producers of progesterone to sustain high levels of progesterone later in pregnancy which
peak at the end of gestation (Tuckey, 2005; Cole, 2010). Dysregulation of progesterone
and hCG can have harmful effects during pregnancy. Reduced levels of progesterone are
associated with threatened miscarriage (Ku et al., 2018) and trophoblastic disease can lead
to significant increases in a subunit of hCG, chorionic gonadotropin beta (CGB) (Kumar
& Magon, 2012). Therefore, trophoblasts are critical in the regulation of hormones and
proper placental development.

1.3.1

Placental differentiation

Implantation occurs when the blastocyst attaches to the uterine lumen epithelium (Ji et al.,
2013). Following implantation, proliferative, undifferentiated cytotrophoblast (CTB) cells
are derived from trophectodermal cells comprising the outer layer of the blastocyst
(Pollheimer et al., 2018). CTBs differentiate through two predominant pathways into
villous cytotrophoblasts (VT) or extravillous cytotrophoblasts (EVTs) (Figure 3) (Ji et al.,
2013). In the VT pathway, CTBs differentiate and fuse into multinucleated
syncytiotrophoblasts (STBs) to form a layer on chorionic villi that is in direct contact with
maternal blood and thus lacks the expression of the classical class I human leukocyte
antigens (HLA) to provide immune tolerance (Ji et al., 2013). CTBs continuously fuse with
the overlaying syncytium to provide fresh cellular components as apoptotic material is
released as syncytial knots (Ji et al., 2013). The syncytium at the maternal-fetal interface
produces and regulates hormones (i.e., hCG); regulates immunological responses; and
facilitates the transfer of nutrients, hormones, gases, and wastes (Than et al., 2014).
Differentiated EVTs proliferate and invade the decidua and myometrium as interstitial
EVTs which fuse into the terminally differentiated giant cells (Al-Nasiry, 2009; Ji et al.,
2013). Alternatively, differentiated endovascular EVTs can invade the maternal spiral
arteries to remodel the vasculature providing increased blood and oxygen flow to the fetus
(Ji et al., 2013).
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Figure 3. Cytotrophoblast differentiation occurs through two main pathways: villous
cytotrophoblasts and extravillous cytotrophoblasts.
CTB progenitor cells differentiating towards the EVT pathway proliferate and migrate to
invade the decidua and myometrium and become giant cells or promote maternal
vascularization as endovascular EVTs. CTBs can also differentiate towards the VT
pathway to fuse into STBs which has a variety of functions. Adapted from (Tarrade et al.,
2001).
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STB differentiation is initiated by increased 3',5'-cyclic adenosine monophosphate (cAMP)
levels via activated adenylyl cyclase which converts adenosine triphosphate (ATP) to
cAMP (Ji et al., 2013). cAMP induces downstream molecules including protein kinase A
(PKA) and exchange protein directly activated by cAMP (Epac) (Figure 4) (Kusama et al.,
2018). PKA mediates the phosphorylation of cyclic AMP response element binding protein
(CREB) as well as activates p38 MAPK leading to increased transcription of glial cells
missing-1 (GCM1), a transcription factor essential for cell fusion, and Ovo like
transcriptional repressor 1 (OVOL1) (Kusama et al., 2018). Other pathways including
MAPK kinases and transforming growth factor  (TGF-)−activating kinase 1 are also
reported to activate p38 kinase (Zhang & Liu, 2002). Signal transducer and activator of
transcription 5B (STAT5B) has also been shown to regulate cell fusion and is suggested to
target GCM1. GCM1 then activates ERVWE1, an endogenous retroviral gene abundantly
expressed in placental tissues (Hua et al., 2018). This gene codes for syncytin-1 which is
upregulated along with syncytin 2 to promote CTB fusion into STBs (Blond et al., 2000;
Hua et al., 2018). The PKA-CREB pathway also leads to an increase of NR4A3 which can
result in a decrease in syncytin 2 to regulate the degree of syncytialization (Kusama et al.,
2018). Alternatively, Epac may induce cell fusion through Ras-related protein 1 (RAP1)
activation (Kusama et al., 2018). RAP1 in turn activates calcium/calmodulin-dependent
protein kinase 1 (CaMK1) which phosphorylates GCM1 (Gupta et al., 2015). A variety of
other signaling pathways are involved in STB fusion and differentiation including the p38
mitogen-activated protein kinases (MAPK), wingless-related integration site (Wnt), janus
kinase-signal transducer and activator of transcription (JAK/STAT), phosphatidylinositol3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR), and TGF-
superfamily pathways (Gupta et al., 2015). However, these associations are less well
characterized. Cell fusion ultimately leads to increased hCG and LGALS13 expression
(Orendi et al., 2010; Kusama et al., 2018). Whether LGALS16 is upregulated in a manner
similar to the closely related LGALS13 gene remains to be elucidated. Previous literature
has also found that cytokines, hormones, protein kinases, transcription factors (i.e., KLF6),
proteases and fusion proteins regulate the fusion of VTs (Ji et al., 2013; Racca et al., 2015).
Myosin-II and tissue stiffness may also mechanically regulate STB morphology, fusion,
and hormone release (Ma et al., 2020).
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Figure 4. cAMP-mediated differentiation signaling pathway.
cAMP induces placental differentiation via PKA and Epac mediated pathways.
Downstream effector molecules upregulate the transcription of genes essential for cell
fusion (i.e. GCM1) leading to an increase in hCG, LGALS13 and potentially LGALS16.
Adapted from (Kusama et al., 2018).

11

Improper trophoblast differentiation and placental function can result in the development
of miscarriage, stillbirth, recurrent pregnancy loss, and preeclampsia, a disorder
characterized by hypertension and proteinurea during pregnancy (Pabinger et al., 2001;
Than et al., 2014; Huppertz, 2018). For example, errors in trophoblast fusion can result in
the release of apoptotic material activating an inflammatory maternal response leading to
preeclampisa (Gauster et al., 2009). Despite their importance, the molecular mechanisms
governing human trophoblast differentiation require further investigation. Galectins have
been found to be associated with placental development and thus may be involved in
mechanisms underlying this pathology.

1.3.2

Placental immune tolerance

Placental immune tolerance is an essential adaptation that suppresses the maternal immune
response to the fetus while maintaining normal infection defense against non-self-antigens
(Wang & Li, 2020). In pregnancy, the embryo and placenta are semi-allografts, exposing
the maternal immune system to paternal-fetal antigens (Kieffer et al., 2019). Despite the
direct contact between the placental/fetal membranes and maternal blood/tissues,
immunological rejection is not triggered (Kanellopoulos-Langevin et al., 2003; Bai et al,
2022). Various mechanisms exist to suppress the immune response. Trophoblasts regulate
the activity, differentiation, and induction of uterine natural killer (NK) cells, decidual
macrophages, and regulatory T cells (Treg), respectively (Wang & Li, 2020). Moreover,
trophoblasts express and secrete immune inhibitory molecules targeting macrophages,
natural killer cells, dendritic cells (DCs), T cells, or myeloid-derived suppressor cells
(MDSCs) (Wang & Li, 2020). The syncytiotrophoblast is also densely covered with
glycoproteins which inhibits activated maternal leukocytes (Arkwright et al., 1994; Petty
et al., 2006). Galectin expression in trophoblasts also serves to regulate placental immune
tolerance (Than et al., 2009).
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1.3.3

Galectin expression in the placenta

Placental trophoblasts express galectins-1, -3, -7, -10, -13, -14, and -16. This intricate
network of galectins is regulated by fetal sex, hormones, oxygen tension, epigenetics,
pathogens, and inflammatory mediators (Jovanović Krivokuća et al., 2021). Consequently,
galectin expression profiles vary in different trophoblast cell populations as well as during
development and differentiation. For example, VT cells express galectins -1, -3 and -8 and
CTBs express galectins-3 and -9 (Jovanović Krivokuća et al., 2021). STBs and EVTs
express galectins-1, -3, -7, and -8. STBs also express galectins-10, -13, -14, and -16 (Than
et al., 2009; Jovanović Krivokuća et al., 2021). While many galectins are widely expressed
in a variety of tissues (i.e., galectins-1 and -3), galectins-13, -14, and -16 are placentaspecific which may indicate their uniquely evolved role at the feto-maternal interface.

Studies have shown galectins to be involved in trophoblast differentiation processes
including placental immune tolerance, invasion, proliferation, angiogenesis, and cell fusion
(Figure 5). Altered and incorrect galectin expression is also associated with different
pregnancy pathologies. These include pregnancy loss, gestational diabetes mellitus,
inflammation, infection, pre-eclampsia, and intrauterine growth restriction (Jovanović
Krivokuća et al., 2021).

Placental specific galectins (LGALS13, LGALS14, LGALS16), particularly LGALS16, are
exclusively expressed in STBs and they are proposed to play a key role in regulating and
preventing the maternal immune response through T cell apoptosis (Than et al., 2014).
These three galectin genes are highly conserved and located in a cluster on chromosome
19 (Than et al., 2014). The correct expression of galectins-13, -14, and -16 has been shown
to be essential for proper reprogramming of the transcriptional activity of the trophoblast.
If the expression of this placenta specific gene cluster is impaired, disorders such as preeclampsia can occur (Than et al., 2014). The predicted loci, LOC148003, was distinguished
as galectin-16 in 2009 and its monomeric structure was only elucidated in 2021 (Than et
al., 2009; Si et al., 2021). Given its recent discovery, extremely limited literature exists on
LGALS16 and its role in trophoblastic differentiation. Therefore, it is a novel feature of my
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Figure 5. Overview of galectin functions in the placenta.
Proposed galectin functions during placental development. Syncytiotrophoblast (STB);
cytotrophoblast (CTB); extravillous trophoblast (EVT); endovascular trophoblast (EnVT);
progesterone (PRG); human chorionic gonadotropin (hCG). Adapted from (Jovanović
Krivokuća et al., 2021).
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study.

1.3.4

Cell models of trophoblastic differentiation

The human placental choriocarcinoma cell lines, BeWo and JEG-3, are well-established in
vitro models for investigating the role of galectins in the differentiation of CTB cells
(Orendi et al., 2010; Poloski et al., 2016). These two cell models differ as BeWo cells are
more similar to VTs and undergo fusion during differentiation, while JEG-3 cells are more
similar to EVTs as they express some EVT markers (i.e. HLA-G), are invasive, and
undergo little fusion compared to BeWo cells (Collett et al., 2012; Tilburgs et al., 2015;
Drwal et al., 2018). A study comparing gene expression in BeWo and JEG-3 cells treated
with forskolin to induce cAMP and ultimately differentiation found 32 altered genes
between the two cell lines highlighting their differences and genes which may play key
roles in cell fusion (Msheik et al., 2019).
Upon treatment with 8-bromo-cyclic adenosine 3′,5′-monophosphate (8-Br-cAMP), both
BeWo and JEG-3 cells are stimulated to differentiate into STB-like cells (Burnside et al.,
1985; Chen et al., 2013). This occurs via PKA-induced activation which upregulates
fusogenic transcription factors, certain galectins (i.e., LGALS13), and the biomarker of
differentiation, CGB (Orendi et al., 2010). However, CGB is also expressed independently
of PKA and cell fusion (Orendi et al., 2010) which allows JEG-3 cells to express this
marker despite undergoing little fusion. These cell models are thus excellent tools that can
be used in experiments investigating the role, function, and regulation of LGALS16 during
8-Br-cAMP-induced differentiation.

1.4 Thesis Overview
Galectins are involved in the differentiation of a variety of cell types (Tazhitdinova &
Timoshenko, 2020). Current literature has shown that galectin-16 is tissue-specific to the
placenta and is significantly upregulated in differentiated STBs treated with cAMP
directly, or forskolin, an inducer of cAMP. However, the reasoning for this relationship
between LGALS16 and placental development is unclear. Gaining a better understanding
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of the regulation and expression of galectin-16 during placental differentiation can help
elucidate its potential role as an important regulator of placental development.
Transcription factors unique to the promoter region of LGALS16 and molecules upstream
in the cAMP pathway may mediate LGALS16 expression during trophoblastic
differentiation. Moreover, recent studies from the Timoshenko laboratory have shown that
galectin expression and secretion can be driven by O-GlcNAcylation, which alters in
differentiated versus progenitor cells (Sherazi et al., 2018; Tazhitdinova & Timoshenko,
2020; Gatie et al., 2022). Therefore, understanding how inhibitors of upstream transcription
factors and O-GlcNAcylation affect LGALS16 expression during differentiation can reveal
the regulatory mechanisms of LGALS16. Additionally, generating LGALS16 CRISPR/Cas9
knockout cells and examining phenotypic effects on STB differentiation can unveil the
functional role of galectin-16 and whether it plays a critical role in placental differentiation
processes.

This study aims to examine the effects of transcription factor inhibitors, O-GlcNAc
modulation, and galectin-16 knockouts on LGALS16 and CGB expression to provide novel
insights into the regulation and functional role of galectin-16. Considering a unique
association of galectin-16 with placental development, I will test the hypothesis that
galectin-16 is an essential regulator of trophoblast differentiation which is guided
through different cAMP-mediated signaling pathways. The rationale behind this study
is that galectin-16 is highly restricted in its expression to differentiated placental cells.
Chapter 2 provides bioinformatics analysis of available databases on galectin-16 and
insights into LGALS16 expression in different cell lines and tissues. Experimental
techniques were also used to identify LGALS16 and transcription factor expression during
placental differentiation using two cell lines, BeWo and JEG-3. Chapter 3 dives deeper into
the regulation and function of galectin-16 by examining the effects of biochemical
inhibitors of predicted transcription factors and O-GlcNAc enzymes to examine their
effects on LGALS16 during differentiation. Further, LGALS16 CRISPR/Cas9 knockouts
were generated to determine phenotypic consequences on placental differentiation.
Together, these chapters provide a comprehensive overview into the regulation and role of
galectin-16 as a novel biomarker of placental differentiation.
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Objective 1: To perform bioinformatics analysis of available databases on galectin-16
expression in different human tissues and cells as well as potential transcriptional and posttranscriptional regulators of galectin-16 expression.

Objective 2: To study changes in the expression of LGALS16 in BeWo and JEG-3 cell lines
in the context of trophoblastic differentiation.

Objective 3: To examine the role of potential transcription factors and O-GlcNAc
homeostasis in regulating LGALS16 expression and trophoblastic differentiation.

Objective 4: To characterize how the LGALS16 CRISPR/Cas9 knockout changes the
capacity of JEG-3 cells for trophoblastic differentiation.
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Chapter 2

2

Expression, Regulation, and Functions of the Galectin16 Gene in Human Cells and Tissues

2.1 Introduction
Galectins comprise a family of soluble β-galactoside binding proteins, which regulate key
biological processes including cell growth, differentiation, apoptosis, and immune
responses (Timoshenko, 2015; Allo et al., 2018; Johannes et al., 2018; Tazhitdinova &
Timoshenko, 2020). Sixteen galectin genes have been identified in animal kingdoms, 12
of which are expressed in humans. Galectins share a conserved carbohydrate recognition
domain (CRD) and they are subcategorized into prototype, tandem-repeat, or chimeric
types according to the number of CRDs and structural features. Prototype galectins contain
one CRD and include galectins -1, -2, -5, -7, -10, -11, -13, -14, -15, and -16. Tandemrepeat galectins contain two homologous CRDs connected by a linker of ~70 amino acids
and include galectins-4, -6, -8, -9, and -12. The only chimera-type galectin is galectin-3,
which contains one CRD linked to a non-lectin N-terminal proline/glycine-rich domain.
Galectins form a network of proteins to perform glycan-dependent and glycan-independent
functions both intra- and extracellularly (Vladoiu et al., 2014; Johannes et al., 2018;
Tazhitdinova & Timoshenko, 2020). Intracellularly, galectins have multiple binding
partners and primarily function via glycan-independent mechanisms to regulate processes
such as cell growth, apoptosis, and pre-mRNA splicing among others (Vladoiu et al., 2014;
Patterson et al., 2015; Tazhitdinova & Timoshenko, 2020). Extracellular galectins are
secreted from cells through unconventional mechanisms (Johannes et al., 2018; Popa et al.,
2018) and can bind to glycoligands on the cell surface or glycoproteins in the extracellular
matrix to promote cell adhesion and migration (He et al., 2006) or bind to specific cell
surface receptors to facilitate their cross-linking and transmembrane signaling (He et al.,
2006; Than et al., 2012; Nabi et al., 2015; Johannes et al., 2018).
Galectin expression profiles vary significantly between different cells and tissues. Some
galectins are commonly expressed with low tissue specificity, e.g., galectin-1 and galectin3, while others are highly-tissue specific (Johannes et al., 2018). LGALS16 was
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characterized in placental tissue by Than and co-authors (Than et al., 2009) and together
with two other galectins (LGALS13 and LGALS14) was found to be upregulated in
differentiated trophoblast cells to confer immunotolerance at the maternal–fetal interface
(Than et al., 2014). These three galectin genes are located in a cluster of four human
protein-coding galectin genes on chromosome 19 and they are proposed to have
evolutionarily emerged to sustain hemochorial placentation in anthropoids (Than et al.,
2009). The correct expression of placenta-specific galectins is an important part of proper
reprogramming of the transcriptional activity of the trophoblast (Than et al., 2014). This
involves the differentiation and fusion of villous cytotrophoblasts into a multinucleated
syncytium that is in direct contact with maternal blood and is responsible for facilitating
gas, nutrient, and waste exchange between the mother and fetus, mediating hormonal
regulation, and forming an immunological barrier during pregnancy (Than et al., 2014).
Differentiated extravillous trophoblasts proliferate, invade, and remodel the maternal spiral
arteries to provide blood flow and nutrients to the fetus (Pollheimer et al., 2018).
Dysregulation of this placenta-specific gene cluster containing LGALS16 is associated with
disorders such as preeclampsia, which can have a high rate of fatality for both the mother
and fetus (Than et al., 2014; Pollheimer et al., 2018; Blois et al., 2019).
Currently, experimental studies on LGALS16 are limited, although multiple microarray
datasets and bioinformatics resources contain relevant information. Here, I use
experimental and bioinformatical approaches for examining expression, regulation, and
functions of LGALS16 to position this galectin within the complex galectin network in cells
and to identify directions for future studies.

2.2 Materials and methods
2.2.1

Bioinformatics data and tools

Microarray and RNA-sequencing data were extracted from the Gene Expression Omnibus
(GEO) Profiles, which contained 287 datasets for LGALS16 (accessed on 2 November
2021), considering the following criteria: (1) inclusion of only controls and untreated
cell/tissue samples, (2) inclusion of only cases with positive gene expression values for
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matched ACTB (a housekeeping gene), LGALS1 (a low tissue specific galectin), and
LGALS16 genes, and (3) deletion of few datasets, which report enormous deviations (>100folds) from average expression levels of ACTB and LGALS1 genes. In silico prediction of
transcription factor binding sites in LGALS16 gene DNA sequence was performed with
PROMO version 3.0.2 software, which utilized version 8.3 of TRANSFAC database
(Messeguer et al., 2002; Farré et al., 2003). The dissimilarity index for the transcription
factor search was set at 0% to limit the number of non-specific matches. Ensembl Release
104 was used to extract the sequence of the 2 kb promoter region of the gene (accessed on
24 August 2021). Four different online platforms were used and compared to predict
putative miRNA targets for LGALS16 including Diana Tools (Paraskevopoulou et al.,
2013), miRabel (Quillet et al., 2020), miRDB (Chen & Wang, 2020), and TargetScan
(Agarwal et al., 2015). The Human Protein Atlas (HPA) (Uhlén et al., 2015), GenBank
(Clark et al., 2016), and Protein Data Bank (PDB) (Berman et al., 2000) were exploited for
searching the relevant structures, sequences, and expression patterns of LGALS16 based on
the gene symbol.

2.2.2

Cell cultures

Placenta choriocarcinoma BeWo and JEG-3 cell lines (kindly provided by Dr. Renaud,
Department of Anatomy and Cell Biology, Western University, London, ON, Canada)
were cultured in Dulbecco’s Modified Eagle Medium/Ham’s F12 medium and RPMI-1640
medium, respectively, supplemented with 10% or 8% fetal bovine serum, 100 IU/mL
penicillin, and 100 μg/mL streptomycin. Cell cultures were maintained in a CO2-incubator
at 37°C and 5% CO2. To induce trophoblastic differentiation, cells were grown in 6-well
plates and treated with 250 μM of 8-Br-cAMP (cat. # B7880, Sigma-Aldrich, Oakville,
ON, Canada) for 48 h (BeWo cells) or 36 h (JEG-3 cells). Over the time of these treatments,
cell culture media was replaced one time for BeWo cells after 24 h of growth and two times
(every 12 h) for JEG-3 cells to avoid accumulation of acidic metabolites.
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2.2.3

Gene expression analysis

The total RNA pools were isolated from cell monolayers using 1mL TRIzol® reagent (cat.
# 15596018, Ambion, Carlsbad, CA, USA) per well of a 6-well plate and RNA quantified
using the Nanodrop 2000c UV-Vis spectrophotometer (ThermoFisher, Waltham, MA,
USA). RNA with a 260/280 nm ratio in the range of 1.8-2.0 was considered high quality.
For cDNA synthesis with the Advanced cDNA Synthesis Kit, 1 μg of RNA sample was
used (cat. # 801-100, Wisent, Montreal, QC, Canada). For both the control and 8-Br-cAMP
treatments, four biological replicates (RNA isolated from different cell passages) were
completed for BeWo cells and three biological replicates were completed for JEG-3 cells.
The conventional and quantitative polymerase chain reaction (PCR) analyses were used to
assess the mRNA expression levels for following genes: ACTB, CGB3/5 (biomarkers of
trophoblastic differentiation), and LGALS16. The oligonucleotide PCR primers
for LGALS16 (forward

5′-ATTTGCGAGTGCACTTAGGC-3′

and

reverse

5′-

GACACACGTAGATGCGCAAG-3′, PCR amplicon length of 132 bp) targeting exon 3
(Figure 6) were designed using Primer-BLAST tool at NCBI (Ye et al., 2012).
Oligonucleotide primers for ACTB (forward 5′-TCAGCAAGCAGGAGTATGACGAG-3′
and reverse 5′-ACATTGTGAACTTTGGGGGATG-3′, PCR amplicon length of 265 bp)
and CGB3/5 (forward

5′-CCTGGCCTTGTCTACCTCTT-3′

and

reverse

5′-

GGCTTTATACCTCGGGGTTG-3′, PCR amplicon length of 109 bp) were available
elsewhere (Timoshenko, 2011; Renaud et al., 2015). To run conventional PCR, reaction
mixes (10 μL 2X Taq FroggaMix (cat. # FBTAQM, FroggaBio, Toronto, ON, Canada), 2
μL forward and reverse primer mixture from 10 μM stock, 7 μL nuclease free water, and 1
μL template cDNA) were loaded into a T100 Thermal Cycler (Bio-Rad Laboratories,
Mississauga, ON, Canada) and amplified using the following PCR regime: 94°C for 3 min;
26 cycles of 94°C for 30 s, 56°C for 30 s, 72 °C for 60 s; and 72°C for 10 min; and held at
4°C. The PCR products were separated on a 2% agarose gel as described earlier
(Timoshenko et al., 2016) and the gel was imaged using the Molecular Imager® Gel Doc™
XR+ (Bio-Rad) to confirm the expected size of PCR amplicons. For primer validation,
bands were excised and then used with the Gel/PCR DNA Fragments Kit (Geneaid)
according to the manufacturer’s protocol and sent to Robarts Research Institute (London,
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A

B

Figure 6. LGALS16 gene structure and the mRNA sequence.
(A) LGALS16 (4735 bp) is located on chromosomal band 19q13.2 and contains 4 exons
(ENSG00000249861). (B) NCBI reference sequence of LGALS16 mRNA
(NM_001190441.3). Each exon is highlighted with red, orange, blue, and black
representing exons 1, 2, 3, and 4, respectively. The protein coding sequence (CDS)
is indicated in capitals while UTRs in small characters. The oligonucleotide
sequences for PCR amplification are boxed.
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ON, Canada) for sequencing. Sequences were then aligned to sequences in the BLAST®
database to verify fidelity. The quantitative PCR was performed in the CFX Connect™
Thermocycler using the SsoAdvanced Universal SYBR® Supermix kit (cat. # 1725274,
Bio-Rad Laboratories, Mississauga, ON, Canada). To quantify ACTB, CGB3/5, and
LGALS16 expression, three technical replicates were performed for each gene and sample
of control or 8-Br-cAMP treated BeWo and JEG-3 cells. Amplification specificity was
verified by the detection of a single melt peak for each PCR amplicon. Relative transcript
levels were quantified by the Livak method (2−∆∆CT) and normalized to the reference
gene, ACTB. To assess the expression levels of 84 genes encoding human transcription
factors, the RT2 Profiler™ PCR Array Kit (cat. # PAHS-075ZD-2, Qiagen, Toronto, ON,
Canada) was used following the protocols provided by the manufacturer. One technical
replicate of the control and 8-Br-cAMP treated cells was completed for each gene tested.

2.2.4

Statistical analysis

Statistical analysis was performed using GraphPad Prism 9 for Windows, version 9.1.2
(GraphPad Software, San Diego, CA, USA) and the data were presented as mean ± SD.
One-way analysis of variance (ANOVA) was used to determine statistical significance
across treatments followed by Tukey’s honestly significant difference test to detect which
means were statistically significant at a value of p < 0.05.

2.3 Results and discussion
2.3.1

Molecular characteristics of galectin-16 gene and
recombinant protein

The LGALS16 gene structure and molecular details were described by Than and co-authors
(Than et al., 2009). LGALS16 (4735 bp) is located on chromosomal band 19q13.2, spans
from bases 39,655,913 to 39,660,647, and contains 4 exons (Figures 6A,B). LGALS16 is
found only in primates and is part of the chromosome 19 gene cluster containing four
protein-coding genes (LGALS10, LGALS13, LGALS14, LGALS16) (Than et al., 2009;
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A

B

Figure 7. Protein sequence and structure of recombinant galectin-16.
(A) The 142 amino acid sequence is 16.6 kDa for the galectin-16 protein. Each color
corresponds to the exon from which the amino acids were encoded with red, orange, blue,
and black representing exons 1, 2, 3, and 4, respectively. The anti-parallel -sheets of Fface (F1–F5) and S-face (S1-S6) strands as well as a short -helix are showed. (B) The
crystal structure was extracted from Protein Data Bank (available online: rcsb.org, accessed
on 6 September 2021), PDB ID: 6LJP.
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Than et al., 2014; Blois et al., 2019; Ely et al., 2019). The diversification and evolutionary
origin of this cluster, including LGALS16, is thought to be related to placenta development
and mediated by transposable long interspersed nuclear elements (LINEs), which are
commonly found at the boundaries of large inversions and gene duplication units (Singer,
1982; Than et al., 2009; Weckselblatt & Rudd, 2015). The relevant rearrangements and
subsequent gains and losses of duplicated genes and pseudogenes are proposed to have
enabled anthropoids to sustain highly invasive placentation and placental phenotypes, such
as longer gestation for larger offspring and an increased body to brain size ratio (Than et
al., 2009).
To the best of my knowledge, no studies are available on native galectin-16 at the protein
level whereas recombinant protein has been produced and tested. The crystal structure of
recombinant galectin-16 and its mutants was solved by Si and co-authors (Si et al., 2021).
Recombinant galectin-16 is a monomeric protein, which is composed of 142 amino acids
and has a typical galectin structure of the CRD β-sandwich with two sheets formed by six
β-strands on the concave side (S1–S6) and five β-strands on the convex side (F1–F5)
(Figure 7). This group also showed that galectin-16 lacks lactose-binding ability unless
arginine (Arg55) is replaced with asparagine in S4 β-strand. In comparison, an earlier
report showed that recombinant galectin-16 and two other human galectins (galectin-13
and galectin-14) can bind lactose–agarose beads and are efficiently and competitively
eluted by lactose (Than et al., 2009). More insights into this discrepancy are required
considering multiple interfering factors, mutations/replacements of amino acids within the
CRD, and different study designs. Regardless, both glycan-dependent and glycanindependent interactions might be essential for galectin-16 similar to other galectins
(Johannes et al., 2018).

2.3.2

Expression patterns and functions of LGALS16 in cells and
tissues

Experimental studies focusing on LGALS16 are limited and an essential source of relevant
information about this gene is the Gene Expression Omnibus (GEO), a data repository for
microarray and RNA-sequencing data (Barrett et al., 2013). Overall, 287 datasets are
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available on GEO (November 2021 search) reporting LGALS16 expression in 52 types of
tissues and various cell lines based on the following platforms: Affymetrix Human Genome
(n = 27), Affymetrix Human Gene (n = 151), Agilent (n = 31), Human Unigene (n = 1),
Illumina Human (n = 82), MCI Human (n = 1), NuGO (n = 1), and Sentrix Human (n =
15). Quantification of differences in LGALS16 expression between different platforms is
challenging. However, evaluation of gene expression values within the same GEO datasets
demonstrates that LGALS16 can be classified as a gene with relatively low expression in
comparison with LGALS1 (a widely expressed galectin with a low tissue specificity)
and ACTB (a common housekeeping gene) (Table 1). Indeed, regardless of the platform,
average GEO percentile rank of expression for LGALS16 measured with different arrays
ranged 4–32% on a scale of 1–100% while the range was 63–100% for LGALS1 and 94–
100% for ACTB. Available GEO profiles do not

contain relevant datasets

with LGALS16 for placenta for comparison, however, the Human Protein Atlas (HPA)
reports tissue-specific overexpression of LGALS16 in placenta followed by brain tissues
and retina (Figure 8A). The biological meaning and reasons of overexpression
of LGALS16 in these diverse tissues is unknown and requires further investigations in the
context of developmental biology. For instance, the complex mechanisms of the placenta–
brain axis of cell development (Rosenfeld, 2021) could be addressed in terms of the unique
association of LGALS16 with these tissues.
In comparison with tissues, HPA reports the expression of LGALS16 mRNA only in two
human cell lines including placental choriocarcinoma cell line BeWo and testicular
teratoma cell line SuSa, which probably can be used as appropriate systems to explore the
biological role of LGALS16 gene (Figure 8B). Human syncytiotrophoblasts, which are
terminally differentiated placental cells, can also serve as a strong positive control
for LGALS16 overexpression (Than et al., 2009; Than et al., 2012; Than et al., 2014).
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Table 1. Comparative expression of LGALS16 in human tissues and cells from the
Gene Expression Omnibus database.
Names of cells or tissues

GEO accession
number

ACTB

LGALS1

LGALS16

Sample
Size

Acetabular labrum cells

GDS5427a

12.682 ± 0.150

12.057 ± 0.107

2.949 ± 0.0093

3

Acute lymphoblastic leukemia cell
line RS4;11
Acute myeloblastic leukemia cell
line Kasumi-1
Acute promyelocytic leukemia cell
line NB4
Adipocyte progenitor cells
(subcutaneous)
Adipocyte progenitors from deep
neck
Bone marrow CD34+ cells (chronic
myeloid leukemia)
Bone marrow plasma cells

GDS4043b

13.861 ± 0.017

11.487 ± 0.033

0.4023 ± 0.607

2

GDS5600a

11.965 ± 0.025

6.455 ± 0.299

2.918 ± 0.036

3

GDS4180a

13.130 ± 0.035

10.823 ± 0.031

3.650 ± 0.108

3

GDS5171a

13.523 ± 0.038

13.397 ± 0.112

4.597 ± 0.251

6

GDS5171a

13.469 ± 0.057

13.208 ± 0.177

4.505 ± 0.094

6

GDS4756a

13.524

11.137

3.050

1

GDS4968a

11.990 ± 0.226

8.714 ± 0.515

3.052 ± 0.257

5

Brain frontal cortex

GDS4758

a

13.402 ± 0.125

96.333 ± 0.840

4.632 ± 0.249

18

Brain hippocampus

GDS4758a

13.477 ± 0.130

11.133 ± 0.375

4.659 ± 0.300

10

Brain hippocampus

GDS4879

a

12.113 ± 0.409

9.076 ± 0.232

3.177 ± 0.177

19

Brain temporal cortex

GDS4758a

13.560 ± 0.131

11.189 ± 0.280

4.749 ± 0.193

19

Breast cancer cell line MCF-7

GDS2759

b

15.884 ± 0.030

13.752 ± 0.153

6.053 ± 0.237

2

Breast cancer cell line MCF-7

GDS4972a

13.029 ± 0.038

12.439 ± 0.083

3.892 ± 0.066

3

Breast cancer cell line MCF-7

GDS4090

a

13.087 ± 0.019

9.566 ± 0.100

2.827 ± 0.405

3

Breast cancer cell line MDA-MB-231

GDS4800a

13.875 ± 0.007

13.565 ± 0.042

5.189 ± 0.085

3

Bronchial smooth muscle primary
cells
Bronchopulmonary neuroendocrine
cell line NCI-H727
Burkitt lymphoma cell line
Namalwa
Burkitt lymphoma cell line Raji

GDS4803

11.629 ± 0.175

11.533 ± 0.041

3.181 ± 0.095

3

GDS4330a

11.978

5.715

3.808

1

GDS4978a

13.468 ± 0.187

8.005 ± 0.073

3.916 ± 0.297

3

GDS4978a

13.367 ± 0.093

8.052 ± 0.141

3.962 ± 0.019

3

Colorectal adenocarcinoma cell line
SW620
Embryonic kidney cell line HEK-293

GDS5416

e

16.400 ± 0.362

17.280 ± 0.043

2.766 ± 0.554

2

GDS4233a

10.330 ± 0.050

7.109 ± 0.098

3.757 ± 0.328

4

Endothelial progenitor cells

GDS3656

c

15.397 ± 0.174

13.845 ± 0.457

8.018 ± 0.103

11

Esophagus biopsies

GDS4350a

12.617 ± 0.230

8.062 ± 0.507

3.255 ± 0.208

8

Gastrointestinal neuroendocrine cell
line KRJ-1
Germinal center B cells

GDS4330

12.135

9.592

2.859

1

GDS4977a

9.793 ± 0.373

8.438 ± 0.225

6.723 ± 0.538

5

Gingival fibroblasts

GDS5811

a

13.628 ± 0.101

13.770 ± 0.174

3.674 ± 0.140

2

Heart (left ventricle)

GDS4772a

11.293 ± 0.361

10.672 ± 0.377

2.941 ± 0.030

5

Heart (left ventricle)

GDS4314

a

12.142 ± 0.365

11.052 ± 0.223

3.344 ± 0.154

5

Heart (right ventricular)

GDS5610a

11.930 ± 0.255

10.934 ± 0.044

3.637 ± 0.181

2

a

a
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Hepatocellular carcinoma cell line
HepG2
Keratinocytes

GDS5340a

13.259 ± 0.039

11.256 ± 0.054

4.281 ± 0.327

3

GDS4426a

12.679 ± 0.056

11.147 ± 0.236

3.804 ± 0.138

6

Lung carcinoma cell line A549

GDS4997a

10.970 ± 0.044

12.187 ± 0.049

2.418 ± 0.072

3

Lung carcinoma cell line H460

GDS5247

12.504 ± 0.043

11.111 ± 0.063

3.439 ± 0.117

3

Lung microvascular endothelial cell
line CC-2527
Lymphoblastoid cell line TK6

GDS2987b

32061 ± 7366

15158 ± 2227

8.100 ± 9.051

2

GDS4915a

13.365 ± 0.061

11.161 ± 0.323

4.005 ± 0.327

2

Lymphoblastoid cell line TK6

GDS4916a

13.940 ± 0.058

12.023 ± 0.130

4.061 ± 0.357

2

Medulloblastoma tumor tissue

GDS4469

a

13.099 ± 0.302

9.490 ± 0.801

4.005 ± 0.839

15

Melanoma cell line A-375

GDS5085a

13.888 ± 0.011

13.474 ± 0.101

4.618 ± 0.045

3

Melanoma cell line FEMX-I

GDS3489

16.04 ± 0.354

16.04 ± 0.354

0.550 ± 1.061

2

Melanoma cell line Hs294T

GDS5670a

11.353 ± 0.245

10.349 ± 0.097

2.149 ± 0.585

2

a

d

Microglia cell line HMO6

GDS4151

13.545

12.231

2.979

1

Myotubes from musculus obliquus
internus
Pancreatic neuroendocrine cell line
QGP-1
Peripheral blood CD34+ cells
(chronic myeloid leukemia)
Peripheral blood CD4+ T cells

GDS5378a

13.224 ± 0.099

12.925 ± 0.114

2.840 ± 0.057

4

GDS4330a

12.057

5.749

3.031

1

GDS4756a

13.414 ± 0.049

11.144 ± 0.578

2.974 ± 0.140

2

GDS5544a

13.598 ± 0.053

9.707 ± 0.247

4.584 ± 0.126

4

Peripheral blood cells

GDS4240a

11.825 ± 0.084

7.307 ± 0.154

1.506 ± 0.112

7

Renal adenocarcinoma cell line 786O
Retinal pigment epithelia primary
cells
Retinal pigmented epithelium cell
line ARPE-19
Skeletal muscle (vastus lateralis)
primary cells
Skeletal muscle tissue

GDS5810

a

12.902 ± 0.030

12.809 ± 0.015

5.753 ± 0.031

2

GDS4224a

13.407 ± 0.110

11.842 ± 0.449

3.468 ± 0.367

4

GDS4224a

13.288

11.946

3.646

1

GDS4920a

13.649 ± 0.084

13.385 ± 0.114

4.609 ± 0.136

12

GDS4841a

9.400 ± 0.190

11.486 ± 0.247

2.786 ± 0.355

5

Skin cancer cell line RT3Sb

GDS5381a

13.409 ± 0.062

8.775 ± 0.114

3.539 ± 0.252

4

Skin epidermis

GDS3806

c

15.139 ± 0.141

9.534 ± 0.370

7.909 ± 0.469

7

Visceral adipose tissue (omentum)

GDS4857a

11.875 ± 0.352

11.488 ± 0.416

4.666 ± 0.754

8

a

Notes: The means ± SD of available gene expression values are shown. The GEO
datasets originated from different platforms: a Affymetrix Human Gene 1.0 ST Array, b
Sentrix Human-6 Expression BeadChip, c Sentrix HumanRef-8 Expression BeadChip, d
MCI Human HEEBOChip 42k oligo array, and e Agilent-014850 Whole Human Genome
Microarray 4 x 44K G4112F.
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A

B

Figure 8. The normalized expression of LGALS16 mRNA in human tissues and cells
from HPA datasets.
(A) LGALS16-positive cases out of 55 tissue types; (B) LGALS16-positive cases out of 69
cell lines. The data were retrieved on 28 November 2021.
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To develop experimental models for studying LGALS16 functions and regulation, I
examined gene expression in BeWo cells and an additional placental cell line JEG-3 in the
context of trophoblastic differentiation. The expression of LGALS16 mRNA was
significantly increased in both cell lines after 36 h (JEG-3 cells) and 48 h (BeWo cells)
treatment with a potent cell-permeable and metabolically stable activator of cAMPdependent protein kinase 8-Br-cAMP (250 μM), which coincided with upregulation
of CGB3/5, genes encoding chorionic gonadotropin subunits 3 and 5 (Figure 9). As
chorionic gonadotropin is one of the biomarkers of placenta and trophoblastic
differentiation, my results suggest classifying LGALS16 to the same category of biological
molecules. Other studies also reported significant upregulation of LGALS16 in association
with processes of cellular differentiation, even if the basal levels were relatively low. Thus,
treatment of BeWo cells with forskolin, an inducer of cyclic adenosine 3′,5′monophosphate

(cAMP),

stimulated

trophoblastic

differentiation

and

simultaneous LGALS16 overexpression (Than et al., 2014). An interesting example
of LGALS16 upregulation was reported in a model of intestinal differentiation of Caco-2
cells induced by a combined treatment with dexamethasone and p44/42 MAPK inhibitor
PD98059 (Inamochi et al., 2014). Therefore, LGALS16 may deserve further attention as a
factor associated with processes of cellular differentiation and tissue development.
An important function of galectin-16 as well as placental galectin-13 and galectin-14 is the
ability to induce apoptosis of CD3+ T cells, which was detected by flow cytometry of cells
double-stained with annexin-V-FITC and propidium iodide (Than et al., 2009).
Considering the high expression of galectin-16 in differentiated trophoblasts, the apoptotic
mechanism might contribute to the immune tolerance at the maternal-fetal interface
reducing the danger of maternal immune attacks on the fetus and enabling anthropoid
primates to evolve long gestation periods while retaining highly invasive placentation. The
details of this regulation are obscure since there are no studies addressing the secretion of
galectin-16 from trophoblasts. However, intracellular EGFP-tagged recombinant galectin16 was readily localized in the nucleus and cytoplasm of transfected cells including, HeLa,
293T, HCT-116, SMMC-7721 and Jurkat cells (Si et al., 2021). In fact, the nuclear staining
was much stronger than in the cytoplasm suggesting that the transport of galectin-16 into
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A

B

Figure 9. LGALS16 expression in human placental choriocarcinoma cell lines, BeWo
and JEG-3.
Cells were treated with 8-Br-cAMP (250 M) for different periods of time to induce
syncytiotrophoblast differentiation. (A) BeWo cells (n = 4); (B) JEG-3 cells (n = 3).
Agarose gels on the left confirm the expected size of PCR amplicons. Bar graphs show the
fold changes in the expression of LGALS16 and CGB3/5 genes obtained by qPCR, which
were quantified by the Livak method (2−ΔΔCT) using ACTB as a reference gene. Data are
presented as means ± SD; means with the same letter are not significantly different from
each other (Tukey’s post hoc HSD test, p > 0.05).
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the nucleus might play a role in regulating intranuclear processes. These authors showed
that the binding partner of galectin-16 is c-Rel, a member of the NF-κB family of
transcription factors (TFs), which is involved in the regulation of multiple processes such
as apoptosis, inflammation, immune responses, tumorigenesis, cell growth and
differentiation (Park & Hong, 2016; Si et al., 2021). All NF-κB family members,
including c-Rel, have a conserved N-terminal DNA-binding/dimerization domain, known
as the Rel homology domain (RHD) (Hayden & Ghosh, 2011). Recombinant galectin-16
strongly binds to the RHD which might inhibit c-Rel and prevent activation of antiapoptotic genes, such as Bcl-2 and Bcl-xL, promoting T-cell apoptosis during pregnancy
(Si et al., 2021). An additional aspect of LGALS16 functions may contribute to the rescue
of glucose restriction-induced cell death in a model of a whole genome gain-of-function
CRISPR activation using human mitochondrial disease complex I mutant cells (Balsa et
al., 2020).

2.3.3
2.3.3.1

Transcriptional
LGALS16

and

post-transcriptional

regulation

of

Transcription factors

Multiple TFs can be involved in the regulation of LGALS16 expression based on the
presence of specific response elements in the promoter regions of the gene. Original
analysis of retrotransposons within the 10 kb 5′ UTR by Than and co-authors demonstrated
that the LGALS16 promoter has binding sites for GATA2, TEF5, and ESRRG, which are
also involved in the regulation of important trophoblast-specific genes such
as ERVWE1 (marker of cell fusion), CGA, and CGB3 (markers of chorionic gonadotropin
production, a hormone released by differentiated trophoblasts to maintain pregnancy)
(Than et al., 2014). The contribution of these TFs in regulating LGALS16 expression was
claimed to vary, especially with decreased regulation from GATA2, due to the specific
layout and properties of transposable elements (L1PA6 and L1PREC2) within the 5′UTR
of this gene as compared to two other placental genes, LGALS13 and LGALS14. Additional
shared TFs for the placental galectin gene cluster include TFAP2A and GCM1, which have
binding sites within ALU transposable elements next to L1PREC2. Experimental evidence
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of this regulation was confirmed in a model of forskolin-induced differentiation of primary
trophoblasts, which revealed time-dependent upregulation of LGALS16 in parallel with the
expression of TEAD3, ESRRG, GCM1, and ERVWE1 (Than et al., 2014). It is interesting
to note that this study did not reveal the effect of 5-azacytidin on LGALS16 expression in
BeWo trophoblast cells as compared to other upregulated placental galectins, which
suggested a minor role of DNA methylation in the context of LGALS16 regulation.
To enrich this analysis, I used human choriocarcinoma cell line JEG-3 and Qiagen
RT2 Profiler™ PCR Array to test changes in the mRNA transcript levels of 84 TFs during
trophoblastic differentiation induced by 8-Br-cAMP. Overall, 60 TFs were upregulated in
this assay including three top genes encoding Jun B proto-oncogene (JUNB), SMAD
family member 9 (SMAD9), and activating transcription factor 3 (ATF3) (Figure 10). Since
all of these three genes are expressed in placenta and brain tissues (Han et al., 2008; Nuzzo
et al., 2014; Ma et al., 2015; Uhlén et al., 2015; Walcott et al., 2018; Knyazev et al., 2019),
which are LGALS16-positive, this observation provides a new insight into possible
transcriptional regulation of this gene. JUNB and ATF3 belong to a family of TFs with a
basic leucine zipper DNA binding domain, with JUNB preferentially binding to the 12-Otetradecanoylphorbol-13-acetate response element sequence and ATF3 binding to the
cAMP response element in promoters with the consensus sequence, TGACGTCA (Garces
et al., 2018). They are subunits of activating protein 1 (AP-1) TFs, which function as
homodimers or heterodimers in association with other members of JUN, FOS, ATF, and
MAF protein families (Garces et al., 2018). JUNB was reported to be directly involved in
processes of trophoblastic cell syncytialization (Cheng et al., 2004; Shankar et al., 2015),
while upregulation of ATF3 was associated with cellular stress responses (Jadhav & Zhang,
2017; Knyazev et al., 2019; Wang et al., 2021), decidualization (Wang et al., 2021), and
preeclampsia (Moslehi et al., 2013). In comparison, SMAD9 is activated by bone
morphogenic proteins (BMPs), a subfamily of the transforming growth factor-β (TGF-β)
family (Han et al., 2008; Tsukamoto et al., 2014). Although some BMPs such as BMP-4
can be regulated in a downstream manner from the cAMP pathway (Heo & Fujiwara,
2011), the connection between SMAD9 and cAMP is still unclear. GATA2 was found to
be slightly upregulated, which may suggest that the enrichment of L1PREC2 in the 5′UTR
still plays a role in regulating LGALS16 despite the insertion of L1PA6 (Than et al, 2014).
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Figure 10. Changes in the expression of genes encoding TFs in JEG-3 cells.

Cells were treated with 8-Br-cAMP (250 M) for 36 hours to induce trophoblastic
differentiation and Qiagen RT2 Profiler TM PCR Array kit was used to assess fold changes
in gene expression between differentiated and control cells presented as a heatmap.
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Interestingly, CREB1, a major regulator downstream of the cAMP pathway was not
upregulated in this RT-qPCR array analysis suggesting that post-translational modification
and transcriptional activation might be essential for this TF.
I further analyzed the 2 kb region upstream from the transcription start site of LGALS16 by
extracting the sequence from Ensembl (Release 104) and performing in silico analysis of
TF-binding sites using PROMO virtual laboratory with a 0% dissimilarity index. Putative
binding sites for seventeen TFs were identified, which may represent specific response
elements, enhancers, or silencers (Figure 11). To reveal common patterns in the expression
of the predicted TFs, I watched for their protein levels in two LGALS16-positive tissues,
the cerebellum and placenta, using the expression scores (high, medium, low) available at
HPA. Protein expression level was determined using immunohistochemical data which
was manually scored for the fraction of stained cells. The protein was then classified into
one of 4 categories: not detected, low, medium, or high expression. Within this set of data,
two TFs (CEBPβ and TFII-I) were characterized by high protein expression levels, seven
TFs had variable levels (GR, NFAT1, p53, STAT4, TCF-4E, TFIID, and YY1), four TFs
(ERα, FOXP3, Pax5, and PR A) showed low expression, and no HPA data were available
for GRα, GRβ, PR B, and XBP-1 in these tissues (Figure 12). Thus, the role of the
predicted TFs in tissue-specific transcriptional regulation of LGALS16 can be different and
remains to be studied.
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Figure 11. In silico screening of putative transcription factor binding sites for the
LGALS16 gene.
There are multiple binding sites for 17 transcription factors within the 2 kb promoter
region upstream the transcription start site of LGALS16 gene as detected by PROMO.
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Figure 12. Protein expression patterns of predicted transcription factors for
LGALS16 regulation in the cerebellum and placenta.
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2.3.3.2

miRNAs

Post-transcriptional control of mRNA availability for protein synthesis depends on
miRNAs which can hybridize to complementary sequences in protein-coding mRNAs at
the 3′ untranslated region and either block protein translation or induce mRNA degradation
(Fabian et al., 2010). Multiple miRNAs were predicted to target the LGALS16 transcript
by bioinformatics tools, such as Diana Tools (Paraskevopoulou et al., 2013), miRabel
(Quillet et al., 2020), miRDB (Chen & Wang, 2020), and TargetScan (Agarwal et al.,
2015), which use different algorithms and methods. A robust application of these tools
using default options shows that five miRNAs (hsa-miR-3155a, hsa-miR-3155b, hsa-miR4689, hsa-miR-4778-5p, hsa-miR-6783-5p) are predicted by all four of these online
platforms (Figure 13). These miRNAs among others can be considered as prospective
candidates

for

regulating

the

stability

and/or

translational

potential

of

the LGALS16 transcripts, especially in relevant tissues such as placenta and brain. Indeed,
a significant decrease in hsa-miR-4778-5p expression during gestation in exosomes from
maternal blood was associated with preterm birth pregnancies (Menon et al., 2019).
Expression of hsa-miR-3155a was significantly upregulated in the anterior cingulate cortex
of deceased patients with major depressive disorder (Yoshino et al., 2020). In comparison,
the expression of hsa-miR-4689 was downregulated in exosomes isolated from the plasma
of patients with mesial temporal lobe epilepsy with hippocampal sclerosis compared to
controls (Yan et al., 2017). Differential expression of exosomal hsa-miR-4689 and hsamiR-6783-5p was reported in patients with intracranial aneurysms (Liao et al., 2020).
Human miRNA tissue atlas confirms expression of hsa-miR-3155a, hsa-miR-3155b, hsamiR-4689, and hsa-miR-4778-5p in brain among other tissues at variable levels (Ludwig
et al., 2016). Unraveling possible mechanisms of miRNA-mediated regulation of galectin16 in these tissues awaits future research.
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Figure 13. Putative miRNAs targeting LGALS16 mRNA transcript.

Five miRNAs are unanimously predicted by four different online platforms such as Diana
Tools, miRabel, miRDB, and TargetScan.
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2.3.4

LGALS16 and human diseases

Dysregulation of the placenta-specific gene cluster containing LGALS16 is associated with
a pregnancy complication known as preeclampsia, which can be fatal for both the mother
and fetus. As such, LGALS16 together with LGALS13 and LGALS14 were confirmed to
satisfy the criteria of placenta enriched genes in a comprehensive study of RNA-Seq
datasets from 302 placental biopsies (Gong et al., 2021). However, although increasing
expression of LGALS13, LGALS14, and LGALS16 was observed during forskolin-induced
syncytialization and differentiation of primary trophoblasts and BeWo cells in culture,
only LGALS13 and LGALS14 were downregulated in preeclampsia with no significant
changes of LGALS16 (Than et al., 2014). Remarkably, LGALS16 does not show sex-biased
expression

depending

on

the

chromosomal

sex

of

the

fetus

while LGALS13 and LGALS14 are notably elevated in fetal male placentas based on the
chorionic villus transcriptome (Braun et al., 2021). These aspects of galectin network
regulation remain unclear in the context of placental disorders and development.
Alterations in the expression or mutations of LGALS16 have been also reported for several
other diseases and based mostly on microarray and RNA-Seq analysis, although the
application of this gene as a biomarker is still unknown. Gene expression profiling with
RNA sequencing data revealed that LGALS16 was detected as an upregulated gene in
fusiform gyrus tissue sections of 219 autopsy-confirmed Alzheimer’s cases versus 70
neurologically normal age-matched controls (Vastrad & Vastrad, 2021). LGALS16 was
also recognized as a brain tissue-specific gene within genome-wide associations with
several neuroimaging psychiatric traits (Zhao et al., 2021). Further, LGALS16 was
expressed two-fold higher in chronic myeloid leukemia granulocytes compared to controls
(Čokić et al., 2015). Copy number variations were identified in chromosome 19 for
multiple genes including LGALS16 in association with clinical features, such as
histological type, ethnicity, disease stage, and familial history of breast cancer using tumor
samples from a Brazilian cohort (Rodrigues-Peres et al., 2019). In addition, LGALS16 was
determined to be a moderate impact variant associated with autism spectrum disorder,
consisting of a missense single nucleotide variant (SNV), which was reported as
detrimental

by

bioinformatic

tools

SIFT

and

PolyPhen-2

(Santos

et

al.,
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2019). LGALS16 also had greater SNVs within the 3′ flank region with one or more
mutations in patients with diffuse large B-cell lymphoma (Arthur et al., 2018). Moreover,
a LGALS16 SNP was revealed to be associated with insulin secretion in a cohort of African
Americans (Keaton et al., 2016). This study also showed that interactions between
this LGALS16 SNP and others, such as an intergenic SNP upstream of the LYPLAL1 gene,
have also been associated with type 2 diabetes risk. The LGALS16 transcript was one of
the top 50 down-regulated mRNA present in the exosomes isolated from the cerebrospinal
fluid in patients with meningeal carcinomatosis in comparison with healthy controls
(Cheng et al., 2021).

2.4 Conclusions
Although the galectin-16 gene was described more than 10 years ago (Than et al., 2009),
the regulation, functions, and clinical aspects of this tissue-specific molecule are largely
unexplored. Primary association of LGALS16 with placental tissue has been challenged by
its detection in brain tissues and several cancer cell lines as followed from available
microarray and RNA-seq databases. There are bioinformatics indications that the
expression of LGALS16 changes in association with Alzheimer’s disease, chronic myeloid
leukemia, breast cancer, B-cell lymphoma, and type 2 diabetes. Although LGALS16 was
not significantly impacted at the gene level in preeclampsia, there remain questions
regarding regulation at the protein level, which cannot be properly addressed at this time
due to the absence of commercially available specific galectin-16 antibodies. The results
obtained with recombinant galectin-16 are promising, but there is still a gap in our
understanding of why the expression of endogenous galectin-16 protein has not been
reported. Nevertheless, among the possible functions of galectin-16 in these and other
tissues, its contribution to the regulation of cellular differentiation and programmed cell
death (apoptosis) warrants special attention. Lastly, the use of proper cell culture models
and the examination of multiple factors (transcription regulators and miRNA) is evidently
the first line of study to position galectin-16 within a complex galectin network in cells.
The generation of galectin-16-specific antibody and LGALS16 knockout cell lines using

49

CRISPR/Cas9 technology might be required steps to unravel the role and significance of
this molecule in the context of cell biology.
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3

Molecular mechanisms regulating LGALS16 expression
in conjunction with trophoblastic differentiation

3.1 Introduction
Galectins are a family of multifunctional β-galactoside binding proteins that play a key role
in biological processes through glycan-dependent and glycan-independent interactions
both intra- and extracellularly (Sherazi et al., 2018; Tazhitdinova & Timoshenko, 2020).
Intracellular galectins are involved in pre-mRNA splicing and regulate cell growth,
apoptosis, and the cell cycle (Liu et al., 2002; Vladoiu et al., 2014). Extracellular galectins
are non-classically secreted and localized in the extracellular matrix to facilitate
transmembrane signaling for cell adhesion and migration (Johannes, 2018; He & Baum,
2006). Some galectins can be found widely throughout human tissues while others are
tissue-specific. For instance, galectin-16, encoded by the gene LGALS16, is predominantly
expressed in the placenta (Than et al., 2009; Kaminker & Timoshenko, 2021). Tissuespecific expression of galectin-16 may indicate a distinct role in cellular differentiation of
the placenta. Mechanisms modulating galectin expression and function include specific
transcription factors and the availability of glycan ligands (Than et al., 2014; Kamili et al.,
2016).
Placental cell models can be induced to differentiate when treated with 8-bromoadenosine3’,5’-cyclic monophosphate (8-Br-cAMP) which results in the increased expression of
LGALS16 and chorionic gonadotropin beta (CGB), a biomarker of placental differentiation
(Burnside et al., 1985; Chen et al., 2013; Kaminker & Timoshenko, 2021). Downstream
signalling molecules in the cAMP pathway, such as protein kinase A (PKA), exchange
protein directly activated by cAMP (Epac), and the p38 mitogen-activated protein kinase
(MAPK) pathway were included in this study to determine how cAMP mediates its effects
on LGALS16 expression during trophoblastic differentiation (Gerbaud et al., 2015;
Delidaki et al., 2011). Additionally, transcription factors (TF) regulate galectin expression
through unique binding sites in the promoter region (Than et al., 2014). Gene expression
of 84 TFs was investigated experimentally in JEG-3 cells during placental differentiation
and showed the greatest increase in 3 TFs: JUNB, SMAD9, and GATA2 (Kaminker &
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Timoshenko, 2021). In addition, analysis of binding sites in the 5’ untranslated region of
LGALS16 reveals response elements for GATA2 (Than et al., 2014). The specific
mechanisms through which TFs mediate LGALS16 expression is largely unknown and
warrants deeper examination.
Recent studies with a variety of cell lines have demonstrated that protein O-GlcNAcylation
governs the localization and function of galectins. O-GlcNAcylation is a process involving
the post-translational modification of serine and threonine residues of intracellular proteins
with GlcNAc (Kim et al., 2017). Two enzymes, O-GlcNAc transferase and O-GlcNAcase
are involved the addition and removal of GlcNAc, respectively (Yang & Qian, 2017). A
recent model proposes high levels of O-GlcNAcylation are associated with galectin
secretion and cellular differentiation while low levels of O-GlcNAcylation lead to an
increase in intracellular galectins and are associated with the undifferentiated cellular state
(Tazhitdinova & Timoshenko, 2020). Moreover, O-GlcNAcylation levels are associated
with placental development and pathologies. For example, hyperglycemia is associated
with an increase in O-GlcNAcylation and can be harmful for the fetus (Ning & Yang,
2021). The relationship between O-GlcNAcylation and LGALS16 expression during
trophoblastic differentiation requires further inquiry.
To date, there is little data examining the function of galectin-16 during differentiation.
One suggested role of galectin-16 is the regulation of T-cell apoptosis for maternal immune
tolerance at the maternal-fetal interface via interactions with c-Rel, a member of the NFkB family of transcription factors (Than et al., 2009; Si et al., 2020). Genome editing
provides a tool to target and functionally knockout a specific protein by inducing frameshift
mutations with insertions/deletions (indel) of nucleotides in the nucleic acid sequence
(Tuladhar et al., 2019). To gain a better understanding of galectin-16’s role in placental
differentiation, LGALS16 knockout cells were produced using the CRISPR/Cas9 system to
determine phenotypic changes during 8-Br-cAMP-induced differentiation.
This study investigated the upstream regulation of LGALS16 expression, specifically by
using biochemical inhibitors of transcription factors, cAMP signaling pathways, and O-
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GlcNAc homeostasis. Additionally, the downstream effects of galectin-16 on cellular
differentiation were investigated using LGALS16 knockouts.

3.2 Materials and methods
3.2.1

Cell cultures and reagents

BeWo cells were cultured in Ham’s F-12K (Kaighn’s) medium (21127022, ThermoFisher,
Waltham, MA) supplemented with 10% FBS, 100 IU/mL penicillin, and 100 g/mL
streptomycin. JEG-3 cells were cultured in RPMI-1640 medium (11875093,
ThermoFisher) supplemented 8% FBS, 100 IU/mL penicillin, and 100 μg/mL
streptomycin. Cells were subcultured at 80% confluency and maintained at 37C and 5%
CO2.
CellTiter-Glo Luminescent Cell Viability Assay (G7571, Promega, Madison, WI) and
thiazoyl blue tetrazolium bromide (MTT) assay (T0793, Bio Basic, Markham, ON) were
used to assess cell viability. Inhibitors H-89 (10010556), K-7174 (32773), LDN-193189
(11802), U0126 (70970), 8-pCPT-2’-O-Me-Cyclic AMP (17143), ESI-09 (19130), and
SB203580 (13067) were from Cayman Chemicals (Ann Arbor, MI).
O-GlcNAc homeostasis was altered with 2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-5thio--D-glucopyranose (AC), which was kindly provided by Dr. David Vocadlo as per
Material Transfer Agreement between Simon Fraser University and the University of
Western Ontario, and thiamet G (TG) (SML0244) was from Sigma-Aldrich Canada
(Oakville, ON). Trophoblastic differentiation was induced with 8-Br-cAMP (B7880,
Sigma-Aldrich).
Primary antibodies used for immunodot blots and western blots included: RL2 O-GlcNAc
(1:1000; MA1-072); ThermoFisher), β-actin (1:200; sc-47778; Santa Cruz, Dallas, TX),
galectin-1 (1:800; sc-166618; Santa Cruz), galectin-3 (1:200; sc-20157; Santa Cruz), and
CGB (1:3000; PA5-16265; Abcam, Cambridge, UK). Secondary antibodies included antimouse IgG HRP (1:10 000; A16066; ThermoFisher) and anti-rabbit IgG-HRP (1:10 000;
A16096; ThermoFisher). Primary antibodies were diluted in TBS-T, 5% BSA, and 0.1%
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NaN3 and secondary antibodies were diluted in TBST-T, 3% BSA, and 1% non-fat dry
milk.
For Sanger sequencing of LGALS16 CRISPR/Cas9 knockout clonal pools, genomic DNA
was isolated using QuickExtract™ DNA Extraction Solution (Lucigen, Middleton, WI).
PCR was performed with 2X Amplitaq Gold 36 master mix (ThermoFisher) and samples
were purified with QIAquick PCR Purification Kit (Qiagen, Hilden, Germany).

3.2.2

Cell viability assays

Cells were seeded at 2 x 105 cells/mL in 96-well plates with 100 L per well and given 24
hours to adhere. Cell medium was replaced, and cells were treated every 12 hours for 36
hours. For CellTiter-Glo® Assay, cells were equilibrated to room temperature for 30
minutes and 100 L of reagent was then added. Wells were mixed on an orbital shaker for
2 minutes, incubated at room temperature for 10 minutes, and luminescence was recorded
using Instinct™ software. For MTT assays, a 2.5 mg/mL MTT solution was prepared and
20 L were added to each well. Cells were incubated at 37C for 4 hours. Media was
aspirated and 150 L of DMSO was added to each well. The plate was mixed on a shaker
for 30 minutes and read on a BioTek 800 TS Absorbance Reader (Santa Clara, CA) at 570
nm. Dose-response curves were generated for each biochemical inhibitor to determine nontoxic concentrations for cell treatments. Three technical replicate wells were performed for
every treatment and time point. Blank wells containing only media were also assayed with
3 technical replicates. Technical replicates were averaged, and the average of the blank
wells was subtracted from each value. The resultant values were then normalized to the
control wells which were left untreated.

3.2.3

Cell treatments

JEG-3 cells were plated at 1 x 105 cells/mL and 2 x 105 cells/mL for untreated and treated
cells, respectively, in 6-well plates with 2 mL per well. JEG-3 cells were treated with 8
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biochemical inhibitors including: 5 M H-89, 2.5 M K7174, 100 nM LDN-193189, 10
M U0126, 5  SB203580, 10  ESI-09, and 10 M 8-pCPT-2'-O-Me-Cyclic AMP,.
Non-toxic concentrations of inhibitors were selected to target PKA, GATA2, SMAD9,
JUNB, p38/MAPK, and Epac, as well as stimulate Epac, respectively. BeWo cells were
plated at 5 x 104 cells/mL and 1 x 105 cells/mL for untreated and treated cells in 6-well
plates with 2 mL per well. To test the effects of O-GlcNAcylation, BeWo cells in complete
medium were treated for 24 hrs with 25 μM of AC, an OGT inhibitor, or with 10 μM of
TG, an OGA inhibitor. Transcriptional and O-GlcNAc inhibitors were added to cell
cultures with or without 250 M of 8-Br-cAMP for 36 hours before RNA and protein
collection.

3.2.4

Gene expression analysis

RNA isolation, cDNA synthesis, conventional PCR (cPCR), and real-time quantitative
polymerase chain reaction (RT-qPCR) were carried out to measure mRNA expression for
ACTB, CGB3/5, LGALS1, LGALS3, LGALS8, LGALS9, LGALS12, LGALS13, and
LGALS16 as previously described in (Kaminker & Timoshenko, 2021) using the primers
synthesized at BioCorp UWO OligoFactory (Table 2). All primers were validated using
conventional PCR and gel electrophoresis to confirm amplicon size. Bands were excised,
sequenced at Robarts Research Institute (London, ON, Canada), and verified by aligning
resultant sequences on BLAST®. Relative transcript levels were quantified by the Livak
method (2−∆∆CT) and normalized to the reference gene, ACTB.

3.2.5

Protein collection and quantification

After cell treatments, medium was aspirated and cells were washed twice with Dulbecco’s
phosphate buffered saline (DPBS) (0.137 M NaCl, 2.7 mM KCl, 1.1 mM KH2PO4, 0.5 mM
MgCl2•6H2O, 8.1 mM Na2HPO4•7H2O, 0.9 mM CaCl2). Protein lysates were collected
with RIPA buffer (10 mM Tris-HCl, pH 8, 1% Triton X-100, 0.1% SDS, 0.5 mM EGTA,
0.1% sodium deoxycholate, 140 mM NaCl), 100 mM sodium orthovanadate (Na3VO4),
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Table 2. Primers for RT-qPCR to quantify gene expression.

Gene

Primer sequence, 5’ -> 3’

Forward/Reverse

Size

Melting Peak

(bp)
ACTB

CGB3/5

LGALS1

LGALS3

LGALS8

LGALS9

LGALS12

LGALS13

LGALS16

TCAGCAAGCAGGAGTATGACGAG

F

ACATTGTGAACTTTGGGGGATG

R

CCTGGCCTTGTCTACCTCTT

F

GGCTTTATACCTCGGGGTTG

R

CCTGGAGAGTGCCTTCGAGTG

F

CTGCAACACTTCCAGGCTGG

R

CAGAATTGCTTTAGATTTCCAA

F

TTATCCAGCTTTGTATTGCAA

R

TGGGGACGGGAAGAGATCAC

F

TGCCATAAATGCCCAGAGTGTC

R

CTTTCATCACCACCATTCTG

F

ATGTGGAACCTCTGAGCACTG

R

TGTGAGCCTGAGGGACCA

F

GCTGAGATCAGTTTCTTCTGC

R

TATTGCCTTCCGTTTCCGAG

F

GCTCAAATTGTTTGCCATCC

R

ATTTGCGAGTGCACTTAGGC

F

GACACACGTAGATGCGCAAG

R

265

83.5C

109

86.0C

220

89.5C

108

80.0C

172

82.0C

91

83.5C

111

86.5C

125

83.0C

132

82.5C
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100 M PMSF and protease inhibitor cocktail (1 mM AEBSF, 5 mM EDTA, 50 M
leupeptin, and 1 M pepstatin). Lysates were incubated on ice for 10 minutes, passed three
times through a 23G needle, and centrifuged at 10,000 x g for 15 minutes at 4C.
Supernatant was collected and protein concentrations were quantified using a DC Protein
Assay™ (Bio-Rad, Hercules, CA). A Model 3550 Microplate Reader (Bio-Rad) was used
to detect absorbance at 655 nm.
Immunodot blot assays were conducted to determine the O-GlcNAcylation level of cells
using Bio-Dot® Microfiltration apparatus (Bio-Rad). Nitrocellulose membranes (GE
Healthcare, Chicago, IL) were pre-wetted for 10 minutes with Tris-buffered saline (TBS)
(20 mM Tris-HCl, pH 7.5, 500 mM NaCl) and then loaded into the microfiltration
apparatus. Protein extracts were diluted in DPBS (20 g/mL) and 200 L of the diluted
samples were loaded into wells and allowed to immobilize by gravity filtration for 90
minutes. The membrane was then blocked with 3% bovine serum albumin (BSA) and 1%
skim milk in Tris-buffered saline with Tween (TBS-T) (20 mM Tris, pH 7.5, 500 mM
NaCl, 0.05% Tween 20) for 1 hour at room temperature. The membrane was washed 3
times with TBS-T and incubated overnight at 4C with mouse monoclonal pan-specific
primary antibody to O-GlcNAc (RL2) (ThermoFisher). Next, the membrane was washed
3 times with TBS-T and incubated with a goat anti-mouse secondary antibody
(ThermoFisher) at room temperature for 1 hour. Nitrocellulose membranes were developed
with Luminata™ Forte Western HRP Substrate (Millipore) and imaged with the
ChemiDoc® XRS system (Bio-Rad) and Quantity-One® 1-D analysis software (Bio-Rad)
to visualize protein expression. ImageLab software version 5.2 (Bio-Rad) was used for
densitometry to measure the signal intensity of each dot.

Intracellular galectins-1 and -3 as well as CGB protein levels were measured using western
blots. Loading buffer (2% (w/v) SDS, 0.04% beta-mercaptoethanol) was added to protein
lysates. Samples were boiled for 5 minutes, loaded on 4% polyacrylamide stacking gel (25
g protein per lane), and electrophoretically separated by SDS-PAGE in 10% Mini-
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PROTEAN TGX gels (Bio-Rad) at 100 V. Proteins were transferred to PVDF membrane
(Sigma-Aldrich) overnight at 20 V in 4oC using a transfer buffer (25 mM Tris, 190 mM
glycine, 20% methanol). Membranes were blocked with 3% BSA and 1% skim milk in
TBS-T for 1 hour at room temperature, washed 3 times with TBS-T, and then incubated
overnight with primary antibody at 4C. The membrane was washed 3 times the next day
with TBS-T and incubated for 1 hour with secondary antibody. Membranes were imaged
using the same protocols as those for immunodot blots. Western blots were normalized to
-actin.

3.2.6

LGALS16 CRISPR/Cas9 knockouts

A JEG-3 LGALS16 knockout cell pool was purchased from Synthego (Redwood City, CA).
The single guide RNA (sgRNA) sequence, UUUCUACACUGAGAUGAAUG, targeted
exon 3 of LGALS16 near an AGG protospacer adjacent motif (PAM) sequence. To isolate
knockout clones, limiting dilutions of 0.5 cells/well and 1 cell/well were performed in 96well plates with 100 L per well and cell growth was monitored over 8 weeks. Genomic
DNA was isolated with 50 L of QuickExtract™ and samples were placed in the
thermocycler for: 68C for 15 minutes, 95C for 10 minutes, and 4C hold to extract intact
DNA while destroying other cellular components, such as RNA and proteins. PCR was
performed with 25 L 2X Amplitaq Gold 36 master mix, 0.1 M each of LGALS16 primers
designed by Synthego (forward 5′-TGAACAAGTCACAGGCCCAG-3′ and reverse 5′ACACGTAGATGCGCAAGTCA-3′, PCR amplicon length of 392 bp), 2 L genomic
DNA, and 22 L of water for a final volume of 50 L. PCR samples were purified and
subsequently sequenced at Robarts Research Institute (London, ON, Canada). Sanger
sequencing results were analyzed using the Synthego ICE tool.

3.2.7

Statistical analysis

A minimum of three biological replicates were tested for each treatment. Statistical analysis
was performed using GraphPad Prism 9 for Windows, version 9.3.1 (GraphPad Software,
San Diego, CA, USA). One-way analysis of variance (ANOVA) and Tukey’s honestly
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significant difference test were used to determine significant differences between means,
considering p < 0.05 as a statistical threshold.

3.3 Results
3.3.1

Effects of transcription factor and cAMP receptor inhibitors on
galectin gene expression and trophoblastic differentiation in
JEG-3 cells

JEG-3 cells display a significant upregulation of LGALS16 expression during 8-Br-cAMPinduced trophoblastic differentiation (Kaminker and Timoshenko, 2021) yet the pathways
underlying this mechanism are unknown. I sought to identify signaling molecules which
regulate LGALS16 expression during trophoblastic differentiation. Potential transcription
factors and cAMP-dependent molecules were selected according to previous literature.
Biochemical inhibitors of each molecule were used to determine how reducing their
activity would affect galectin gene expression, specifically LGALS16. JEG-3 cells were
then treated with 250 M 8-Br-cAMP alone, inhibitor alone, or inhibitor with 8-Br-cAMP.
Treatment with only 8-Br-cAMP was used as a positive control to quantify changes in
galectin gene expression. Additional galectins were tested to compare whether LGALS16
is regulated in a manner that is unique from other galectins (i.e. LGALS1 and LGALS3) but
more similar to placenta-specific galectins (i.e. LGALS13). Moreover, CGB3/5 expression
was analyzed to determine if LGALS16 is regulated independently of this differentiation
biomarker. A significant change in galectin gene expression between treatment with 8-BrcAMP alone compared to treatment with the inhibitor in addition to 8-Br-cAMP would
indicate that the galectin tested is dependent on and regulated by the inhibited molecule.

To assess these pathways, JEG-3 cell viability was measured under various concentrations
of inhibitors to select non-toxic concentrations for treatments. Based on these results, JEG3 cells were treated with 5 M H-89, 2.5 M K-7174, 100 nM LDN-193189, 10 M
U0126, 5  SB203580, 10  ESI-09, and 10 M 8-pCPT-2'-O-Me-cAMP which
inhibit PKA, GATA2, SMAD9, JUNB, p38/MAPK, Epac, and stimulate Epac,
respectively (Figures 14A-G).
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Figure 14. Cell viability of JEG-3 cells treated with varying concentrations of
biochemical inhibitors.
JEG-3 cells were cultured in 96-well plates were treated with various concentrations of
inhibitors with or without 8-Br-cAMP every 12 hours for 36 hours. After 36 hours, MTT
assay was performed and results were used to calculate the percentage of viable cells which
had been treated with (A) H-89, (B) K-7174, (C) LDN-193189, (D) U0126, (E) SB203580,
(F) ESI-09, and (G) 8-pCPT-2’-O-Me-cAMP, in relation to untreated cells. Cell viability
is presented as the mean  SD (n=3).
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JEG-3 cells treated with 8-Br-cAMP showed a significant 2-fold upregulation of LGALS1
expression (Figure 15). Treatment with U0126, a JUNB inhibitor, led to a significant
increase (P<0.05, 4-fold) in LGALS1 expression during differentiation. Inhibition of Epac
with ESI09 led to a non-significant increase of LGALS1 expression during differentiation
(P=0.5852). No significant changes were seen in cells treated with H-89, K-7174, LDN193189, SB203580, or 8-pCPT-2’-O-Me-cAMP.

LGALS3 expression displayed a slight non-significant increase (P=0.4386) during
trophoblastic differentiation (Figure 16). Inhibition of PKA with H-89 led to a significant
upregulation (P<0.01, 2-fold) of LGALS3 expression during differentiation. JUNB
inhibition via U0126 treatment also showed an increasing trend compared to cells treated
with 8-Br-cAMP alone, however it was not significant (P=0.9998). Inhibitors K-7174,
LDN-193189, SB203580, ESI-09, and the stimulator 8-pCPT-2’-O-Me-cAMP resulted in
no significant changes of LGALS3 expression when used in addition to 8-Br-cAMP.

In regard to LGALS13 expression, JEG-3 cells showed significant increases in LGALS13
under 8-Br-cAMP treatment (P<0.05, P<0.01, P<0.001) (Figures 17A-G). Cells treated
with 8-Br-cAMP and H-89, LDN-193189, or U0126 showed decreasing trends (P=0.1122,
P=0.1122, P=0.7195) in LGALS13 expression while cells treated with ESI-09 showed no
change (P=0.2263). A significant decrease in LGALS13 expression was observed in cells
treated with 8-Br-cAMP and K-7174 (2-fold, P<0.01), SB203580 (3-fold, P<0.01), and 8pCPT-2’-O-Me-cAMP (2-fold, P<0.05).

Similar to LGALS1 and LGALS13, JEG-3 cells treated with 8-Br-cAMP displayed
significant increases in LGALS16 expression (P<0.01, P<0.001, P<0.0001) (Figures 18AG). H-89, K-7174, and 8-pCPT-2-O-Me-cAMP treatment showed non-significant
decreasing trends in LGALS16 expression (P=0.1122, P=0.2449, P=0.2627) between cells
treated with 8-Br-cAMP alone and cells treated with both the inhibitor and 8-Br-cAMP.
No significant changes were seen in cells treated with LDN193189 and U0126 (P=0.8499,
P=9790). Interestingly, JEG-3 cells treated with the p38/MAPK inhibitor, SB203580,
demonstrated a significant decrease (P<0.0001) and 2.4-fold change in LGALS16

68

Figure 15. Effects of inhibitors on LGALS1 expression during trophoblastic
differentiation.
JEG-3 cells were cultured in 6-well plates and treated every 12 hours for 36 hours with
inhibitors alone or in combination with 250 M 8-Br-cAMP. Cells were treated with
inhibitors H-89 (PKA), K-7174 (GATA2), LDN-193189 (SMAD9), U0126 (JUNB),
SB203580 (p38/MAPK), ESI-09 (Epac), and stimulator 8-pCPT-2’-O-Me-cAMP (Epac).
LGALS1 was significantly upregulated during trophoblastic differentiation. Inhibition of
JUNB with U0126 treatment led to a significant increase in LGALS1 expression during
differentiation while inhibition of Epac led to a non-significant increasing trend. Black bars
indicate untreated cells. Grey bars indicate cells treated with 8-Br-cAMP. Values are
presented as mean  SD for control cells (n=15) and for cells treated with inhibitors (n=3).
Different letters indicate significant differences.
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Figure 16. Effects of inhibitors on LGALS3 expression during trophoblastic
differentiation.
JEG-3 cells were cultured in 6-well plates and treated every 12 hours for 36 hours with
inhibitors alone or in combination with 250 M 8-Br-cAMP. Cells were treated with
inhibitors H-89 (PKA), K-7174 (GATA2), LDN-193189 (SMAD9), U0126 (JUNB),
SB203580 (p38/MAPK), ESI-09 (Epac), and stimulator 8-pCPT-2’-O-Me-cAMP (Epac).
LGALS3 did not significantly change during trophoblastic differentiation. Treatment with
H-89 to inhibit PKA led to a significant increase in LGALS3 while treatment with U0126
to inhibit JUNB resulted in a non-significant increasing trend. Black bars indicate untreated
cells. Grey bars indicate cells treated with 8-Br-cAMP. Values are presented as mean  SD
for control cells (n=15) and for cells treated with inhibitors (n=3). Different letters indicate
significant differences.
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Figure 17. Effects of inhibitors on LGALS13 expression during trophoblastic
differentiation.
JEG-3 cells were cultured in 6-well plates and treated every 12 hours for 36 hours with
inhibitors alone or in combination with 250 M 8-Br-cAMP. Cells were treated with
inhibitors (A) H-89 (PKA), (B) K-7174 (GATA2), (C) LDN-193189 (SMAD9), (D) U0126
(JUNB), (E) SB203580 (p38/MAPK), (F) ESI-09 (Epac), and (G) stimulator 8-pCPT-2’O-Me-cAMP (Epac). Treatment with K-7174, SB203580, 8-pCPT-2’-O-Me-cAMP
significantly decreased LGALS13 expression. Black bars indicate untreated cells. Grey bars
indicate cells treated with 8-Br-cAMP. Values are presented as mean  SD (n=3). Relative
transcript levels were quantified by the Livak method (2−∆∆CT) and normalized to the
reference gene, ACTB. Significance is reported according to ****P < 0.0001, ***P < 0.001,
**P < 0.01, *P < 0.05.
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Figure 18. Effects of inhibitors on LGALS16 expression during trophoblastic
differentiation.

JEG-3 cells were cultured in 6-well plates and treated every 12 hours for 36 hours with
inhibitors alone or in combination with 250 M 8-Br-cAMP. Cells were treated with
inhibitors (A) H-89 (PKA), (B) K-7174 (GATA2), (C) LDN-193189 (SMAD9), (D) U0126
(JUNB), (E) SB203580 (p38/MAPK), (F) ESI-09 (Epac), and (G) stimulator 8-pCPT-2’O-Me-cAMP (Epac). Treatment with SB203580 significantly decreased LGALS16
expression

while

ESI-09

significantly

increased

LGALS16

expression

during

differentiation. Black bars indicate untreated cells. Grey bars indicate cells treated with 8Br-cAMP. Values are presented as mean  SD (n=3). Relative transcript levels were
quantified by the Livak method (2−∆∆CT) and normalized to the reference gene, ACTB.
Significance is reported according to ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05.
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expression during differentiation. Additionally, JEG-3 cells treated with Epac inhibitor,
ESI-09, displayed a significant increase (P<0.01) and 1.4-fold change in LGALS16
expression during differentiation.

Untreated JEG-3 cells showed a significant 60-fold increase in CGB3/5 expression, the
biomarker of trophoblastic differentiation, when treated with 8-Br-cAMP to induce
differentiation as expected (P<0.05, P<0.01, P<0.001) (Figures 19A-G). Treatment with
H-89 showed a slight increase (P=0.6852) between control cells treated with 8-Br-cAMP
and cells treated with both the inhibitor and 8-Br-cAMP while GATA2 inhibitor, K-7174,
and p38/MAPK inhibitor, SB203580, demonstrated a decreasing trend (P=0.8174,
P=0.2098). However, none of these changes were significant. Epac inhibitor, ESI-09, and
stimulator, 8-pCPT-2’-O-Me-cAMP, displayed no changes in CGB3/5 expression between
cells only treated with 8-Br-cAMP and those treated with 8-Br-cAMP and
inhibitor/stimulator. In contrast, the expression of CGB3/5 was significantly decreased by
LDN-19189 (1.5-fold, P<0.05) and U0126 (6-fold, P<0.01) which inhibit SMAD9 and
U0126, respectively.

Correlation analysis reveals that LGALS13, LGALS16, and CGB3/5 demonstrate
significant positive correlations in their expression, which suggests common mechanisms
in their regulation (Figures 20A-C).

Overall, LGALS13, LGALS16, and CGB3/5 expression are significantly positively
correlated. LGALS13 and LGALS16 are regulated in a similar manner that is different
from LGALS1 and LGALS3 which supports the hypothesis. However, LGALS13 and
LGALS16 appear to be regulated by different upstream molecules from CGB3/5.
LGALS16 expression during trophoblastic differentiation was only altered when cells
were treated with inhibitors of p38/MAPK and Epac suggesting they may be key
regulators of LGALS16 expression.

73

Figure 19. Effects of inhibitors on CGB3/5 expression during trophoblastic
differentiation.
JEG-3 cells were cultured in 6-well plates and treated every 12 hours for 36 hours with
inhibitors alone or in combination with 250 M 8-Br-cAMP. Cells were treated with
inhibitors (A) H-89 (PKA), (B) K-7174 (GATA2), (C) LDN-193189 (SMAD9), (D) U0126
(JUNB), (E) SB203580 (p38/MAPK), (F) ESI-09 (Epac), and (G) stimulator 8-pCPT-2’O-Me-cAMP (Epac). CGB3/5 was significantly upregulated during trophoblast
differentiation. Treatment with LDN-193189 and U0126 led to a significant
downregulation of CGB3/5 expression. Black bars indicate untreated cells. Grey bars
indicate cells treated with 8-Br-cAMP. Values are presented as mean  SD (n=3). Relative
transcript levels were quantified by the Livak method (2−∆∆CT) and normalized to the
reference gene, ACTB. Significance is reported according to ****P < 0.0001, ***P < 0.001,
**P < 0.01, *P < 0.05.
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Figure 20. Correlations in gene expression between LGALS13, LGALS16, and the
biomarker of trophoblastic differentiation, CGB3/5.
The relative expression of LGALS13, LGALS16, and CGB3/5 in JEG-3 cells ( )
untreated or treated with ( ) H-89 (PKA), ( ) K-7174 (GATA2), ( ) LDN-193189
(SMAD9), ( ) U0126 (JUNB), ( ) SB203580 (p38/MAPK), () ESI-09 (Epac), and ()
stimulator 8-pCPT-2’-O-Me-cAMP (Epac). The correlations between (A) LGALS13 and
LGALS16 (n=30), (B) CGB3/5 and LGALS16 (n=144), and (C) CGB3/5 and LGALS13
(n=30). Cells treated with inhibitor alone are shaded in black and cells treated with
inhibitor in addition to 250 M of 8-Br-cAMP are shaded in grey. A significant
correlation was seen between LGALS13 and LGALS16, LGALS16 and CGB3/5, and
LGALS13 and CGB3/5. Relative transcript levels were quantified by the Livak method
(2−∆∆CT) and normalized to the reference gene, ACTB. Pearson’s correlation test was used
to determine the correlation between gene expression with a statistical threshold of P <
0.05 (n=3).
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3.3.2

Galectin expression profile and O-GlcNAc homeostasis
during trophoblastic differentiation in BeWo cells

An additional mechanism which may regulate galectins during differentiation is OGlcNAcylation. I investigated whether O-GlcNAcylation plays a role in regulating
LGALS16 expression during trophoblastic differentiation. To do so, I first quantified
changes in O-GlcNAcylation and the galectin expression profile of BeWo cells during 8Br-cAMP-induced trophoblastic differentiation.

qRT-PCR was used to detect the mRNA expression levels of LGALS1, LGALS3, LGALS8,
LGALS9, LGALS12, LGALS13, and LGALS16 using cDNA from BeWo cells treated with
250 M of 8-Br-cAMP for 0, 24, or 48 hours (Figures 21A-H). Significant upregulation
of LGALS1 (7-fold, P<0.01), LGALS12 (26-fold, P<0.05), LGALS13 (17-fold, P<0.01), and
LGALS16 (27-fold, P<0.01) expression was detected during differentiation between
control cells and cells treated with 8-Br-cAMP for 48 hours. No significant changes were
observed in LGALS1 and LGALS12 expression between the control and 24 hour treated
cells. LGALS13 and LGALS16 expression was significantly increased (P<0.05) between
cells treated for 24 hours and those treated for 48 hours indicating a time-dependent
increase for both genes. LGALS3 and LGALS9 showed slight decreases but the changes
were not significant (P=0.2947 and P=0.6885). LGALS8 showed slight increases in gene
expression between control and 24 hrs which remained consistent at 48 hrs but the changes
were not significant (P=0.1968) between any time points. Additionally, intracellular
galectin-1 and galectin-3 protein levels did not change significantly during differentiation
(Figure S1).
An immunodot blot was conducted to measure the level of O-GlcNAcylated proteins of
cells treated with 8-Br-cAMP at 0, 24, and 48 hours (Figures 22A & B). Quantification of
the blot using ImageLab (Bio-Rad) showed no significant changes in O-GlcNAcylation
during differentiation at 24 or 48 hrs (P=0.9919, P=0.9847). Of interest, JEG-3 cells also
did not show a significant change in O-GlcNAc homeostasis during trophoblastic
differentiation (Figure S2). It was also noted that JEG-3 cells showed a significantly lower
basal level of O-GlcNAcylation than BeWo cells (Figure S3).
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Figure 21. Galectin expression profiles of undifferentiated and differentiated BeWo
placental cells.
Using RT-qPCR, relative expression levels of all galectins were determined and quantified
using the 2-ΔΔCT method and normalized to housekeeping gene, ACTB. (A) LGALS1, (B)
LGALS3, (C) LGALS8, (D) LGALS9, (E) LGALS12, (F) LGALS13, (G) LGALS16 and (H)
CGB3/5. Differentiation induces the expression of LGALS1, LGALS12, LGALS13,
LGALS16, and CGB3/5. Values are presented as mean  SD (n=4). All statistical analysis
was performed using one-way ANOVA followed by Tukey’s multiple comparisons test
(using Prism 9.3.1). Significant differences are indicated by ****P < 0.0001, ***P < 0.001,
**P < 0.01, *P < 0.05.
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Figure 22. BeWo cells undergoing trophoblastic differentiation show no change in the
global level of O-GlcNAcylated proteins.
Immunodot blot analysis of protein lysates from (A) BeWo cells treated with 250 M 8Br-cAMP for 0, 24, or 48 hours. (B) Quantification of the global level of O-GlcNAcylation
based on densitometry analysis using ImageLab software (Bio-Rad) reveals no change in
O-GlcNAcylation during differentiation. Values are presented as mean ± SD.
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The significant increase in CGB3/5 during 8-Br-cAMP treatment confirms differentiation
of BeWo cells. These results indicate that the global level of O-GlcNAcylation does not
change during differentiation while the expression of LGALS1, LGALS12, LGALS13, and
LGALS16 are significantly increased during differentiation. I next wanted to confirm
whether these changes in galectin expression are dependent on O-GlcNAc homeostasis.

3.3.3

Expression of galectins genes and CGB3/5 did not change in
BeWo cells treated with OGA/OGT inhibitors

O-GlcNAcylation levels in BeWo cells were altered using AC, an OGT inhibitor, and TG,
an OGA inhibitor, to reduce and stimulate O-GlcNAcylation, respectively. Galectin
expression profiling was then completed to assess whether O-GlcNAc homeostasis affects
galectin gene expression.
An immunodot blot assay was performed for cells treated with 25 μM AC or 10 μM TG
(Figures 23A & B). This was done as a control to confirm that the OGA inhibitor promoted
O-GlcNAcylation and the OGT inhibitor diminished global levels of O-GlcNAcylated
proteins. Following densitometry analysis using ImageLab (Bio-Rad) and a one-way
ANOVA analysis as well as Tukey test, there was a significant 2-fold increase (P<0.0001)
in O-GlcNAcylation between control cells and TG treated cells. A significant 2-fold
increase (P<0.0001) was also seen between TG treated cells and AC treated cells. However,
no significant change (P=0.9901) was seen in control cells compared to AC treated cells.
Transcript gene expression levels were measured for cells treated with 25 μM AC or 10
μM TG for 24 hrs relative to untreated cells. qRT-PCR for LGALS1, LGALS3, LGALS8,
LGALS9, LGALS12, LGALS13, and LGALS16 showed no significant changes between any
of the time points for any of the galectin genes tested and specifically for cells treated with
TG (P=0.4732, 0.3192, 0.4979, 0.5415, 0.5834, 0.2986, and 0.4881) (Figures 24A-F).
However, there was a slight downward trend for the expression of LGALS3, LGALS8, and
LGALS12 and a slight upward trend for LGALS13 expression. Similarly, galectin-1 and
galectin-3 levels were not altered with OGA or OGT treatment (Figure S1).
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Figure 23. Global O-GlcNAcylation level in BeWo cells treated with AC, an OGT
inhibitor, and TG, an OGA inhibitor.
Immunodot blot analysis of protein lysates from (A) BeWo cells treated with cell media,
AC, or TG for 24 hours. Quantification of the global level of O-GlcNAcylation based on
densitometry analysis using ImageLab software (Bio-Rad) reveals (B) an increase in OGlcNAcylation in cells treated with TG and no change in cells treated with AC. Values are
presented as mean ± SD. All statistical analysis was performed using PRISM 9.3.1 software
(one-way ANOVA followed by Tukey’s multiple comparisons test). Significance is
reported according to ****P <0.0001.
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Figure 24. RT-qPCR analysis of galectin and CGB3/5 mRNA expression in response
to O-GlcNAc inhibitors.
Relative expression levels of BeWo placental cells treated with 25 mM AC, or 10 mM TG
for 24 hours relative to untreated cells were quantified using the Livak method (2-ΔΔCT) and
normalized to ACTB as a reference gene. (A) LGALS1, (B) LGALS3, (C) LGALS8, (D)
LGALS9, (E) LGALS12, (F) LGALS13, (G) LGALS16, (H) CGB3/5. Values are presented
as mean  SD (n=3). No significant differences among treatments were detected.
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mRNA levels of CGB3/5 were tested in cells treated with O-GlcNAcylation enzyme
inhibitors to determine whether the level of O-GlcNAcylation promotes the expression of
CGB3/5, a biomarker of differentiation. qRT-PCR was used to test the transcript level of
CGB3/5 in cells treated with 25 μM AC or 10 μM TG for 24 hrs relative to untreated cells.
No significant changes were observed in cells with OGA or OGT inhibitors.

These results do not support the hypothesis as O-GlcNAcylation appears to have no
effect on LGALS16 expression or trophoblastic differentiation of BeWo cells. Thus, other
mechanisms such as p38/MAPK and Epac pathways, should be further investigated as
regulatory molecules of LGALS16.

3.3.4

LGALS16 knockout cell pools and their functional properties

After testing signaling mechanisms of LGALS16 expression, I wanted to examine the
functional role of galectin-16 during trophoblastic differentiation. For this analysis, a
LGALS16 knockout pool of JEG-3 cells was generated and obtained from Synthego (Menlo
Park, CA). This pool contained a heterogenous mix of wildtype cells and cells with various
mutations. Thus, the knockout pool needed to be diluted to create a pure genetically
identical clonal population. Due to unavailable antibodies, I verified this clonal population
only at the transcript level.

A limiting dilution and clonal expansion of 0.5 cells per well and 1 cell per well of JEG-3
LGALS16 CRISPR/Cas9 knockout cell pools from Synthego was performed. Sanger
sequencing was performed for 32 clonal pools. After analyzing sequencing results, 5 clonal
pools were selected based on those which had the greatest proportion of mutated cells and
least amount of wildtype cells (Figure S4). Additionally, the original knockout pool from
Synthego with 50% of cells containing a knockout was included for comparison.
Sequencing of clonal pool #31 using the Synthego ICE tool revealed an insertion of 1
nucleotide in 57% of the cell population (Figure 25A) with a model fit of 0.73 indicating
that 73% of the sequences submitted were able to be read. Indels with a percentage of 5%
or lower were ignored as the ICE tool is unable to differentiate these from background
signals, therefore this additional 1% from a 19-nucleotide insertion was ignored. The
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Figure 25. Confirmation of LGALS16 knockout clonal pool #31 via Sanger sequencing
and RT-qPCR.
A JEG-3 LGALS16 knockout (KO) cell pool from Synthego was diluted to 0.5 cells or 1
cells per well and grown to 80% confluency in 96-well plates. Genomic DNA was
extracted, PCR amplified, purified, and sequenced at Robarts Research Institute (London,
ON, Canada). (A) Sanger sequencing results of clonal pool #31 were analyzed using the
Synthego ICE tool demonstrating a LGALS16 KO clonal pool with 57% containing an
insertion of 1 nucleotide and 15% containing wildtype (WT) cells. A model fit of 0.7 or
higher indicated high quality sequencing. Mutants less than 5% can be attributed to
background noise and consequently ignored. (B) The mRNA sequence for exon 3 of the
WT (lowercase) was compared with that of the knockout mRNA sequence (uppercase).
Highlighted in black is the insertion of a nucleotide. This results in a frameshift mutation
and a truncated protein that does not produce amino acids for exon 4. The nucleotides
underlined indicate the premature stop codon. (C) The translated sequence for exon 3 of
the WT was compared with that of the KO mRNA sequence (bolded). The sequence in
black is the changed amino acid sequence which is prematurely terminated.
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knockout (KO) score of 58 can also be reduced to 57. This score takes into account whether
the mutation is a multiple of 3 to report what percentage of mutations are likely to lead to
a frameshift mutation. Analysis of the mRNA sequence and translated protein sequence of
clonal pool #31 in comparison to that of wildtype cells revealed a shift in the reading frame
and a premature stop codon in the third exon (Figure 25B & C). qRT-PCR was used to
measure LGALS16 expression of all 4 selected clonal pools and the original KO pool in
untreated cells and cells treated with 8-Br-cAMP for 36 hours. Clonal pool #31
significantly suppressed (P<0.0001) the expression of LGALS16 with an 8-fold change
(Figure 26). Three of the clonal pools and the original KO pool showed a significant
decrease in LGALS16 expression (P<0.0001) during differentiation while one pool showed
a significant increase in LGALS16 expression (P<0.01) (Figure S5). Although a single pure
clone was not produced, clonal pool #31 was used as a proxy for further testing.

To assess the functional effects of the JEG-3 LGALS16 knockout clonal pool #31, I
investigated CGB3/5 expression and CGB protein levels as markers of trophoblastic
differentiation. Moreover, I assessed morphological changes of the clonal pool in
comparison to wildtype cells.

JEG-3 LGALS16 KO clonal pool #31 showed a significant decrease (P<0.0001) and a 2.5fold change in CGB3/5 expression between WT cells treated with 8-Br-cAMP and
LGALS16 KO cells treated with 8-Br-cAMP (Figure 27A). Other clonal pools were
additionally tested and showed significant increases (P<0.05, P<0.01, P<0.001) in CGB3/5
expression while the original KO pool showed no significant change in CGB3/5 expression
but did show an upward trend (Figure S6).

To verify the changes in KO clonal pool #31 at the protein level, western blots of JEG-3
WT and clonal pool #31 cells were tested during 8-Br-cAMP-induced differentiation. The
KO clonal cell pool #31 showed a decrease of CGB protein levels in comparison with
WT cells (Figure 27B). However, additional replicates need to be completed for
statistical analysis.
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Figure 26. Confirmation of LGALS16 knockout clonal pool #31 via Sanger sequencing
and RT-qPCR.
RT-qPCR of control and LGALS16 knockout (KO) cell mRNA untreated or treated with 8Br-cAMP for 36 hours revealed LGALS16 expression is inhibited under 8-Br-cAMP
treatment. LGALS16 expression was significantly decreased in JEG-3 KO cells. Black and
grey columns indicate untreated and 8-Br-cAMP treated cells, respectively. The data were
quantified using the Livak method (2-ΔΔCT) and normalized to ACTB as a reference gene.
Values are presented as mean ± SD. All statistical analysis was performed using PRISM
9.3.1 software (one-way ANOVA followed by Tukey’s multiple comparisons test).
Significance is reported according to ****P<0.0001.
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Figure 27. Functional effects of LGALS16 knockouts on CGB gene and protein
expression.
JEG-3 LGALS16 knockout clonal pool #31 and wildtype cells were grown in 6-well plates
and either left untreated or treated with 8-Br-cAMP for 36 hours. (A) RT-qPCR of samples
revealed a significant decrease in CGB3/5 expression in the knockout (KO) clonal pool
when treated with 8-Br-cAMP compared to wildtype (WT) cells treated with 8-Br-cAMP.
(B & C) Western blots were completed to assess CGB at the protein level. A decrease of
CGB protein was observed in the KO pool of cells treated with 8-Br-cAMP compared with
wildtype treated cells. However, additional replicates need to be repeated for statistical
analysis. Black and grey columns indicate untreated and 8-Br-cAMP treated cells,
respectively. Significance is reported according to ****P<0.0001, ***P<0.001.
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WT and KO JEG-3 cells from clonal pool #31 were left untreated or treated for 36 hours
with 8-Br-cAMP and imaged (Figure 28A & B). WT JEG-3 cells display epithelial-like
morphology and grow as a confluent monolayer. WT JEG-3 cells treated with 8-Br-cAMP
undergo some fusion. JEG-3 KO cells display similar epithelial-like morphology to WT
cells at low confluency (0 hours). At high confluency (36 hours), untreated KO cells appear
to form clusters. However, both WT and KO cells can grow into a monolayer.

Overall, these results show that the JEG-3 LGALS16 knockout clonal pool #31 resulted in
a significant decrease in CGB3/5 expression and a decrease in CGB protein levels.
Furthermore, some morphological changes are seen between the wildtype and LGALS16
knockout cell pool. These findings support the hypothesis as knocking out LGALS16
suppresses trophoblastic differentiation as indicated by CGB expression.
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Figure 28. Images of JEG-3 WT and LGALS16 KO clonal pool #31 cells at 0 hours of
cellular differentiation vs. 36 hours of differentiation.
JEG-3 cells have epithelial-like morphology and undergo some fusion during trophoblastic
differentiation. (A) Wildtype (WT) and (B) KO cells were left untreated or treated with
250 M of 8-Br-cAMP for 36 hours. There are morphological differences, however both
control and KO cells grow and form a monolayer. All images were taken at 20 ×
magnification.
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3.4 Discussion
Trophoblastic differentiation from cytotrophoblasts to syncytiotrophoblasts is regulated by
a variety of pathways including cAMP-dependent signaling pathways. cAMP activates
Epac-dependent pathways as well as PKA-dependent pathways responsible for activating
p38/MAPK (Gupta et al., 2015). Both lead to an increase in glial cells missing a ultimately
triggering cell fusion and differentiation (Gupta et al., 2015). Galectin-16 is significantly
upregulated during syncytialization in a cAMP-dependent manner along with a number of
transcription factors, such as, JUNB, SMAD9, and ATF3 (Kaminker & Timoshenko,
2021). To investigate the regulation of LGALS16, I selected 6 inhibitors and 1 stimulator
of transcription factors and signaling molecules in the cAMP pathway. For comparison
with tissue-specific LGALS16, I included LGALS1 and LGALS3 which are widely
expressed across different tissues as well as placenta-specific LGALS13 for analysis.

My findings showed that during trophoblastic differentiation of JEG-3 cells, LGALS1,
LGALS13, LGALS16, and CGB3/5, a biomarker of syncytialization, were significantly
upregulated while LGALS3 showed a slight non-significant increase. However, LGALS1
and LGALS3 were expressed at lower levels compared to LGALS13 and LGALS16.
LGALS1 expression was regulated by JUNB while LGALS3 was regulated by PKA. A lack
of data exists on LGALS1 in association with JUNB. However, previous literature has
shown that galectin-1 protein induces BeWo cell fusion and differentiation through the
phosphorylation of MAPK (Hutter et al., 2016). Therefore, although it was not affected by
p38/MAPK inhibitor, U0126, it may instead be upstream of the p38/MAPK signaling
pathway. Although my study found LGALS3 to be regulated by PKA during trophoblastic
differentiation, a study using human leukemia monocytic cell line, THP-1, showed no
change in galectin-3 when cells were exposed to PKA inhibitor, H-89, in addition to
phorbol 12-myristate 12-acetate treatment to induce macrophage differentiation (Kim et
al., 2003). Collectively these findings suggest that galectin-3 is uniquely regulated during
differentiation of different tissue types. Additionally, galectin-1 protein is abundant in
syncytiotrophoblast and absent in villous cytotrophoblast (Jovanović Krivokuća et al.,
2021). In contrast, galectin-3 is present in cytotrophoblasts which may explain its low level
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of expression (Jovanović Krivokuća et al., 2021). Therefore, it would be interesting to see
how the inhibitors affect galectin-1 and galectin-3 protein levels and their localization.

LGALS13 and LGALS16 expression were significantly positively correlated and regulated
in a similar manner by p38/MAPK and Epac. This finding aligns with literature as both
galectins are evolutionarily related in the placenta-cluster of galectins through gene
duplication and the insertion of transposable elements (Than et al., 2014). LGALS13 was
additionally regulated by GATA2 while LGALS16 was not. It has been predicted that
LGALS16 is less regulated by GATA2 than LGALS13 and LGALS14 due to the insertion
of a transposable element insertion, L1PA6, between the promoter region of LGALS16 and
GATA2 binding sites (Than et al., 2014). LGALS13 and LGALS14 do not have this
additional transposable element and therefore, the binding site is closer to their promoter
for greater regulation by GATA2 (Than et al., 2014). The decrease observed in LGALS13
mRNA after treatment with p38 inhibitor, SB203580 has also been found in previous
studies (Costa et al., 2016). Collectively, this data suggests that p38/MAPK and Epac are
key regulators of LGALS13 and LGALS16 during trophoblastic differentiation, but these
galectins can also be uniquely regulated. Interestingly, CGB3/5 expression is significantly
positively correlated with LGALS16 and LGALS13 expression but is regulated through
SMAD9 and JUNB pathways. A study investigating galectin-13 expression in association
with CGB found that these two proteins are partially expressed through independent
pathways (Orendi et al., 2010). This may explain the separate regulatory pathways of
LGALS16 and CGB3/5. However, there may be an additional regulatory molecule signaling
LGALS13, LGALS16, and CGB3/5 which may account for their more tightly correlated
expression. The same study found that CGB3/5 expression was inhibited by H-89 treatment
to inhibit PKA (Orendi et al, 2010). My findings with JEG-3 cells contradict these results.
To further test these results, I treated BeWo cells with 10 M of H-89 inhibitor which was
the same concentration used by Orendi et al but CGB3/5 expression was not affected
(Figure S7). Moreover, they found that H-89 significantly inhibited LGALS13 expression
during differentiation while my findings did not show a significant change in LGALS13 or
LGALS16 expression (Orendi et al, 2010). These differences may be explained through the

92

different differentiator inducers as I used 8-Br-cAMP while the previous paper treated with
forskolin to induce cAMP.

Cellular differentiation is associated with changes in O-GlcNAcylation levels and galectin
expression in a tissue-specific manner (Sherazi et al., 2018; Tazhitdinova & Timoshenko,
2020). Protein glycosylation is a dynamic process responsive to physiological and
pathological stimuli and is regulated by the O-GlcNAcylation enzymes, OGA/OGT
(Laderach et al., 2010; Yang & Qian, 2017). These post-translational modifications result
in altered signaling pathways which are decoded by galectins, -galactoside binding lectins
(Laderach et al., 2010). In my study, I investigated the relationship between galectin
expression and O-GlcNAcylation in a model of cytotrophoblast differentiation into
syncytiotrophoblasts. To do so, I analyzed the galectin expression profile of the human
placental cell line BeWo and tested the effects of O-GlcNAcylation stimulation and
inhibition on galectin expression using OGA/OGT inhibitors, TG and AC, respectively.

Galectin expression profiling of BeWo cells during cAMP-induced differentiation revealed
a significant upregulation of LGALS1, LGALS12, LGALS13, and LGALS16. This suggests
that these four genes may play key roles in trophoblastic differentiation. Increased LGALS1
expression and low LGALS3 expression was consistent with what was observed in JEG-3
cells during differentiation. However, a study in which BeWo cells were treated with
forskolin led to a significant upregulation of LGALS3 (Liu et al., 2016). Currently,
LGALS12 has not been identified as showing significant changes or as having a major role
in placental formation (Jeschke et al., 2013). However, the results of this study show a
significant 26-fold increase in LGALS12 expression between undifferentiated BeWo cells
and those differentiated for 48 hours. Galectin-12 is primarily expressed by peripheral
blood leukocytes and adipocytes and functions to block the G1 phase of the cell cycle
inhibiting cell proliferation (Jeschke et al., 2013). Further investigation into the role of
galectin-12 in trophoblast differentiation is therefore necessary as limited literature exists.
Likewise, LGALS16 in my study showed a 27-fold increase at 48 hrs, revealing a
significant upregulation in differentiated trophoblasts. This is consistent to a study that
performed RT-qPCR on LGALS16 in normal pregnant mothers not in labour and found the
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placental expression to be 1711.5-fold higher than fetal membrane expression (Than et al.,
2009). No changes were seen in intracellular protein levels of galectins-1 and -3 during
differentiation. A study showed that galectin-1 secretion does not change when BeWo cells
undergo forskolin-induced differentiation while BeWo cells treated with chorionic
gonadotropin (hCG) display increased galectin-3 expression and secretion (Yang et al.,
2011; Toudic et al., 2019). Thus, it appears that galectin-1 levels do not change while the
localization of galectin-3 may require further investigation.

As cells differentiated, the global level of O-GlcNAcylated proteins in BeWo and JEG-3
cells did not change. These findings are consistent with previous literature examining
BeWo differentiation into syncytiotrophoblasts (Ruane et al., 2020). In my study, treatment
of BeWo cells with AC showed a decreasing trend in the global O-GlcNAcylation level
however it was not significant. Treatment with TG on the other hand showed the expected
increase in O-GlcNAcyation levels. However, manipulation of O-GlcNAcylation levels
using OGA/OGT inhibitors did not change the expression of galectins between
undifferentiated and differentiated cells. Moreover, OGA/OGT inhibitors had no effect on
the expression of CGB, a marker of differentiation. In a study in which hESCs were treated
with AC, gene expression profiling revealed the increased expression of neuronal markers
suggesting O-GlcNAcylation inhibition plays a direct role in accelerating neuronal
differentiation (Andres et al., 2017). My study did not show changes in galectins that were
consistent with those observed in differentiated cells. Prior investigations have found that
TG does promote syncytiotrophoblast differentiation of BeWo cells (Ruane et al., 2020).
These differing results may be explained as the previous study used GCM1 and OVOL1
which are markers of cell fusion, a characteristic found in

differentiated

syncytiotrophoblasts (Ruane et al., 2020). However, cell fusion has been shown to be
partially independent of CGB expression (Orendi et al., 2010). Therefore, these genes may
be distinctly regulated. Nonetheless, my results suggest that O-GlcNAcylation does not
directly regulate galectin gene expression or cellular differentiation and alternative
mechanisms are likely involved.
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To investigate the functional importance of galectin-16 in trophoblastic differentiation, I
generated JEG-3 LGALS16 KO cells. Due to a lack of availability of galectin-16-specific
antibody, the LGALS16 knockout clonal pool was confirmed with a significant decrease in
LGALS16 expression at the mRNA level. Functional effects of the LGALS16 KO included
the suppression of CGB, the biomarker of differentiation. Additionally, KO cells appeared
slightly morphologically different and formed more clusters but retained the ability to form
a monolayer. Overall, these findings suggest galectin-16 is required for trophoblastic
differentiation.

3.5 Conclusion
This study provides insights into the regulation and functional role of galectin-16.
Trophoblastic differentiation induced by cAMP has been shown to lead to a significant
increase of LGALS16 expression. My findings reveal LGALS16 expression to be mediated
by cAMP-dependent signaling molecules, p38/MAPK and Epac. LGALS1 and LGALS3
appear to be predominantly regulated by JUNB and PKA, respectively. In contrast,
LGALS13 is regulated in a similar manner to LGALS16 suggesting these signaling
mechanisms are conserved with the placenta-specific galectin gene cluster. Moreover,
galectin gene expression, specifically LGALS16, does not appear to be controlled by OGlcNAc homeostasis nor does the differentiation of BeWo cells. JEG-3 LGALS16 KO cells
are a novel feature of this study and lead to a significant reduction in CGB expression. This
indicates the critical role that galectin-16 serves in trophoblastic differentiation. These
studies are only an initial step in elucidating the biological significance of galectin-16.
Future studies using pure clones can provide a clearer picture of the regulation and
functions of galectin-16. Confirmation of galectin-16 knockout cells with galectin-16specific antibody is also a necessary verification step. Moreover, additional functional
assays should be investigated, such as proliferation and apoptosis, to determine galectin16’s functional role in trophoblastic differentiation and the maternal immune tolerance
during pregnancy.
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4

Thesis Summary

Literature on galectin-16 is scarce with most studies focusing on its placenta-specific
expression. While the structure of recombinant galectin-16 was recently elucidated, its
regulation and function were largely unknown. Using bioinformatic analysis and
experimental techniques, I examined the expression, regulation, and functional role of
LGALS16 gene in placental differentiation using BeWo and JEG-3 cell models. In support
of my hypothesis, I have found that galectin-16 may play a critical role in placental
differentiation from cytotrophoblasts to syncytiotrophoblasts which is guided through
cAMP-mediated signaling pathways. Further, my studies provide a deeper understanding
of these regulatory mechanisms and the functional consequences of LGALS16 knockouts.

4.1 LGALS16 expression is tissue-specific and may be
regulated by an intricate system of transcription factors and
miRNAs
Bioinformatics analysis of galectin-16 expression using data from the Human Protein
Atlas revealed that LGALS16 is most highly expressed in placental, retina, and brain
tissue. Further, the Human Protein Atlas only reported LGALS16 expression in BeWo and
Susa cells, a testicular carcinoma cell line (Uhlén et al, 2015). Extraction of data from
Gene Expression Omnibus, reveals LGALS16 can be detected in a number of other
tissues, however, this is at very low levels. These findings demonstrate that galectin-16 is
tissue-specific and may have evolved unique, critical roles in the tissues in which it is
highly expressed. I also completed an in silico analysis to determine potential regulatory
mechanisms of galectin-16, including transcription factors and miRNAs. The program
PROMO was used to analyze the 2 kb promoter region of LGALS16. This identified 17
predicted transcription factors which may be involved in the regulation of galectin-16.
Four programs were used to assess miRNAs which may target galectin-16. Five miRNAs
were recognized by all four programs and can be further investigated. Lastly, LGALS16 is
reported to be associated with a variety of diseases, such as Alzheimer’s disease, breast
cancer, and type 2 diabetes. These findings provide an introduction to the complexity
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underlying the regulatory pathways of galectin-16 and downstream effects. Much of this
data is predicted and needs to be confirmed and explored experimentally.

4.2 LGALS16 expression is significantly upregulated during
trophoblastic differentiation
Investigations related to my second objective confirmed that both BeWo and JEG-3 cell
models undergo trophoblastic differentiation with 8-Br-cAMP treatment as observed with
the significant increase in CGB3/5 expression. RT-qPCR revealed a significant
upregulation of LGALS16 in BeWo cells which is consistent with the literature (Than et
al., 2014). My findings demonstrated a significant increase in LGALS16 expression in a
time-dependent manner during trophoblastic differentiation of JEG-3 for the first time.
These two placental cell lines (BeWo and JEG-3) share similarities in that they can both
be differentiated towards the syncytiotrophoblast with 8-Br-cAMP. However, JEG-3 cells
also express markers of extravillous trophoblasts which are responsible for proliferation
and migration. The maintenance of high LGALS16 expression between the two cell lines
highlights the importance of this galectin for placental differentiation regardless of
trophoblast cell type.

4.3 LGALS16 expression is regulated by p38 and Epac
As part of my third objective, I examined transcription factor and cAMP receptor
inhibitors. Transcription factors in the promoter region were first predicted using the
bioinformatic tool, PROMO. A RT2 Profiler PCR array was then used to experimentally
quantify the changes in gene expression for 84 transcription factors during differentiation
of JEG-3 cells. Signaling molecules in the cAMP pathway were also selected by analyzing
the promoter region of LGALS16 using previous literature. This resulted in the selection of
inhibitors for PKA (H-89), GATA2 (K-7174), SMAD9 (LDN-193189), JUNB (U0126),
p38/MAPK (SB203580), Epac (ESI-09), and a stimulator of Epac (8-pCPT-2’-O-MecAMP). Only p38/MAPK and Epac were found to regulate LGALS16 expression in JEG-3
cells. Moreover, the expression of placenta-specific galectins, LGALS13 and LGALS16 are
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regulated in a similar manner and their expression is significantly positively correlated.
This is different from LGALS1 and LGALS3 which are widely expressed in a variety of
tissues and appear to be regulated by JUNB and PKA, respectively. LGALS16 is not
regulated by GATA2 which aligns with prior predictions based on the insertion of an
additional transposable element between its promoter region and the GATA2 binding site
(Than et al., 2014). Moreover, LGALS16 and LGALS13 expression is significantly
positively correlated with CGB3/5 expression which suggests common mechanisms in
their regulation. In summary, the regulation of LGALS16 expression is unique while
sharing conserved mechanisms with its placenta-specific galectin cluster.

4.4 LGALS16 expression is not mediated by O-GlcNAc
homeostasis
Additional findings from investigations related to my third objective suggest that galectin
expression during trophoblastic differentiation may not be directly mediated by OGlcNAcylation. Galectin expression profiling during trophoblastic differentiation using the
choriocarcinoma cell line, BeWo, revealed the significant upregulation of LGALS1,
LGALS12, LGALS13, and LGALS16. No change in LGALS3, LGALS8, and LGALS9 or
protein levels of galectins-1 and -3 was detected. These results for LGALS1 and LGALS16
are consistent with previous studies while the changes for LGALS12 have not been
previously identified. This provides further support that these galectins, particularly
LGALS16, play a critical role in the proper differentiation of cytotrophoblasts that requires
further investigation. No changes in global O-GlcNAcylation level were seen during
differentiation. Moreover, direct manipulation of OGA/OGT did not affect any of the
galectin genes tested or galectins-1 and -3 at the protein level. It also did not affect gene
expression of CGB3/5, the biomarker of differentiation. These results suggest that the
expression of galectin genes and proteins in BeWo cells during differentiation is
independent of O-GlcNAcylation.
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4.5 Galectin-16 knockouts suppress CGB expression, the
biomarker of trophoblastic differentiation
In regard to my fifth objective, a JEG-3 LGALS16 knockout clonal pool was generated.
Sanger sequencing of the clonal pool identified a single nucleotide insertion in 57% of the
cell population that was sequenced. Further analysis showed that this results in a frameshift
mutation and premature stop codon. Confirmation of the LGALS16 knockout was detected
with a significant decrease in LGALS16 mRNA expression. Fifteen percent of the
population consisted of wildtype DNA indicating the pool was not a pure clone. RT-qPCR
of wildtype and knockout cells that had been treated with 8-Br-cAMP displayed a
significant reduction in CGB3/5 expression. Western blots of protein lysates from wildtype
and knockout cells treated with 8-Br-cAMP also showed a decrease in CGB at a protein
level. This suggests galectin-16 has a significant role in trophoblastic differentiation.

4.6 Limitations of Study Design and Future Directions
A limitation of my study is that the cell models, BeWo and JEG-3, are placental
choriocarcinoma cell lines and therefore possess some differences from primary villous
cytotrophoblasts. However, both are well established models and allow us to gain a deeper
understanding of placental differentiation. Another model that warrants investigations is
brain tissue as it demonstrates a relatively high level of expression of galectin-16. The
biological significance of this specificity is unknown and no studies have been completed
according to my literature search. However, the unique association of galectin-16 with the
placenta-brain-axis of cell development might be a new intriguing mechanism in the
context of developmental biology.

In addition, the biochemical inhibitors for investigations of transcriptional regulation may
produce off-target effects. Nonetheless, these inhibitors can reveal initial insights into
underlying signaling pathways. These can be examined further using silencing RNAs to
provide increased accuracy in targeting specific transcription factors for inhibition.
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Even though O-GlcNAcylation was not found to directly affect galectin gene expression
of BeWo cells in this study, the galectin protein levels of all galectins included in this study
should be tested. Moreover, ELISA kits can be used to assess the extracellular levels of
galectins. O-GlcNAcylation can regulate protein trafficking between the intracellular and
extracellular environments in addition to mRNA expression (Sherazi et al., 2018;).
Therefore, it is possible that rather than affecting galectin gene expression, OGlcNAcylation

may

affect

galectin

localization.

Investigating

the

intracellular/extracellular distribution of galectin proteins during cytotrophoblast
differentiation and with OGA/OGT inhibitors remains to be tested in future studies.

Limitations of the CRISPR/Cas9 system includes the use of a clonal pool rather than an
individual clone and the lack of a primary antibody targeting galectin-16. A primary
antibody from Abcam with cross reactivity for galectins-13/16 was tested. However, the
resultant bands appeared weak and differentiating between the two galectins on the western
blots was not possible. Despite these limitations, the clonal pool showed a significant
decrease in LGALS16 expression at the gene level which suggested it could serve as a proxy
for a pure knockout. A vital step for future studies is to isolate a single clone and to verify
the galectin-16 knockout at the protein level through designing and optimizing a primary
antibody. This will increase the robustness of the data collected as the findings can be
solely attributed to the LGALS16 knockout as opposed to variations in knockout cell pools.
Moreover, repeating the western blot should be completed. Although the bands decrease
in the protein lysates of the LGALS16 knockout clonal pool treated with 8-Br-cAMP, there
is a great deal of variation. This experiment should be repeated to obtain enough samples
for statistics to determine whether CGB protein levels in the knockouts significantly
decrease similar to changes at the mRNA level. In the future, additional functional assays
should be investigated, specifically proliferation and apoptotic assays. If galectin-16 is
essential for trophoblastic differentiation, JEG-3 LGALS16 knockouts should show
increased cell proliferation as their ability to differentiate will be inhibited compared to
wildtype cells which will differentiate leading to a slower growth rate. Additionally,
galectin-16 is suggested to be involved in T-cell apoptosis to mediate the maternal immune
response at the maternal-fetal interface (Si et al., 2021). Therefore, I would expect to see a
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decrease in apoptosis if galectin-16 is knocked out. Understanding the functional
consequences of LGALS16 knockouts in terms of differentiation, cell proliferation, and
apoptosis remains critical to obtaining a holistic view of the role of galectin-16 during
placental differentiation.

4.7 Significance and Practical Applications
Pregnancy complications, such as preeclampsia and fetal growth restriction, are associated
with improper placental development and altered levels of biomarkers. Screening for these
biomarkers can allow for the prediction and diagnosis of pregnancy disorders prior to the
onset of complications. Current biomarkers used include angiogenic factors, such as
placental growth factor and soluble fms-like tyrosine kinase 1 (Stepan et al., 2020). This
information can be applied clinically to prevent certain diseases. For example, women at
high risk for preeclampsia can be administered prophylaxis with aspirin (MacDonald et al.,
2022).

Galectin-13 is expressed in differentiated syncytiotrophoblasts and serves as a biomarker
of preeclampsia. Previous literature has demonstrated that low levels of galectin-13 in the
first trimester and mutations leading to lower LGALS13 expression are associated with
increased risk for preeclampsia (Than et al., 2014; Sammar et al., 2019). A proposed
therapeutic method is to provide galectin-13 as a drug to replenish levels for individuals
with galectin-13 polymorphisms (Sammar et al., 2019). My study clearly shows that
galectins-13 and -16 are significantly upregulated during trophoblastic differentiation via
cAMP-dependent molecules, p38/MAPK and Epac. Moreover, LGALS16 knockout cells
repress CGB expression, a biomarker of differentiation. The importance of galectin-16 for
proper differentiation highlights its role as a novel genetic biomarker of placental
differentiation. While studies have shown LGALS16 expression is not associated with
preeclampsia, the relationship with galectin-16 protein levels is unknown (Than et al.,
2014). Additionally, altered levels of galectin-16 may serve as a biomarker for early
diagnosis of pregnancy disorders other than preeclampsia to allow for preventative
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treatment. Furthermore, galectin-16 may be useful for clinical applications as a therapeutic
target and may be introduced exogenously.

4.8 Concluding remarks
In conclusion, these analyses deepen our understanding of the expression, regulation, and
vital function of galectin-16 in placental differentiation. Importantly, these studies have
illustrated some of the signaling mechanisms regulating LGALS16 expression including
p38/MAPK and Epac which are downstream cAMP receptors. Moreover, LGALS16 is
suggested to be essential for trophoblastic differentiation. Future studies can use
trophoblastic models for genetic manipulation to continue to elucidate the functions of
galectin-16, particularly in association with the maternal immune response. Overall, my
findings indicate that LGALS16 is a novel biomarker of placental differentiation which may
be used as a diagnostic and therapeutic strategy for human choriocarcinoma and placental
pathologies.
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Appendix A: Supplementary Material

Figure S1. Western blots for intracellular protein levels of (A) galectin-1 and (B) galectin3 in BeWo cells treated with 250 M 8-Br-cAMP for 24 and 48 hours as well as BeWo
cells treated with 25 M AC (OGT inhibitor) or 10 M TG (OGA inhibitor) for 24 hours,
n=2. -actin was used as the loading control. Due to low levels of galectin-1, HL60 cells
were included as a positive control. (C) Band intensity of galectin-3 western blots was
quantified using ImageLab software (Bio-Rad). Values are presented as mean ± SD, n=3.
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Figure S2. Immunodot blot analysis of protein lysates from (A) JEG-3 cells treated with
250 M 8-Br-cAMP for 0, 12, 24, or 36 hours. (B) Quantification of the global level of OGlcNAcylation based on densitometry analysis using ImageLab software (Bio-Rad)
reveals no change in O-GlcNAcylation during differentiation. Values are presented as
mean ± SD, n=3.
C

D

Figure S3. Immunodot blot analysis of protein lysates from untreated (A) BeWo cells or
(B) JEG-3 cells. (B) Quantification of the basal level of O-GlcNAcylation based on
densitometry analysis using ImageLab software (Bio-Rad) reveals a significantly lower
level of O-GlcNAcylation in JEG-3 cells compared to BeWo cells. Values are presented as
mean ± SD. Significance is reported according to ****P < 0.0001.
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Figure S4. A JEG-3 LGALS16 knockout (KO) cell pool from Synthego was diluted to 0.5
cells or 1 cells per well and grown to 80% confluency in 96-well plates. Genomic DNA
was extracted, PCR amplified, purified, and sequenced at Robarts Research Institute
(London, ON, Canada). Sanger sequencing results of (A) the original KO pool received
from Synthego and 4 clonal pools, (B) pool #14, (C) pool #15, (D) pool #22, (E) pool #23,
(F) pool #41 were analyzed using the Synthego ICE tool. Pools (A-E) showed mutated
cells, however, none of them could be classified as pure clones due to multiple mutations
in each. Only pool #41 (F) could be classified as a pure heterozygous clone of genetically
identical cells. The equal contribution of sequences of 42% indicates that all cells contain
one chromosome with a deletion of 28 nucleotides and one wildtype chromosome. A model
fit of 0.7 or higher indicated high quality sequencing. Mutants less than 5% can be
attributed to background noise and consequently ignored.
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Figure S5. LGALS16 expression during differentiation of LGALS16 KO clonal pools. RTqPCR of WT and LGALS16 KO cell mRNA untreated or treated with 8-Br-cAMP for 36
hours of (A) the original KO pool received from Synthego, (B) clonal pool #14, (C) clonal
pool #15, (D) clonal pool #22, and (E) clonal pool #23. Quantification revealed LGALS16
expression was significantly inhibited under 8-Br-cAMP treatment for the KO pools and
pools #14, 15, and 22 while pool #23 showed a significant increase in LGALS16 expression.
Black and grey columns indicate untreated and 8-Br-cAMP treated cells, respectively. The
data was quantified using the Livak method (2-ΔΔCT) and normalized to ACTB as a
reference gene. Values are presented as mean ± SD, n=3. All statistical analysis was
performed using PRISM 9.3.1 software (one-way ANOVA followed by Tukey’s multiple
comparisons test). Significance is reported according to ****P<0.0001, ***P<0.001,
**P<0.01, *P<0.05.
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Figure S6. CGB3/5 expression during differentiation of LGALS16 KO clonal pools. RTqPCR of WT and LGALS16 KO cell mRNA untreated or treated with 8-Br-cAMP for 36
hours of (A) the original KO pool received from Synthego, (B) clonal pool #14, (C) clonal
pool #15, (D) clonal pool #22, and (E) clonal pool #23. Quantification revealed CGB3/5
expression was significantly increased under 8-Br-cAMP treatment for all clonal pools and
did not change for the original KO pool. Black and grey columns indicate untreated and 8Br-cAMP treated cells, respectively. The data was quantified using the Livak method (2ΔΔCT) and normalized to ACTB as a reference gene. Values are presented as mean ± SD,
n=3. All statistical analysis was performed using PRISM 9.3.1 software (one-way ANOVA
followed by Tukey’s multiple comparisons test). Significance is reported according to
****P<0.0001, ***P<0.001, **P<0.01, *P<0.05.
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Figure S7. (A) Cell viability of BeWo cells treated with varying concentrations of H-89, a
biochemical inhibitor of PKA. BeWo cells were cultured in 96-well plates and treated with
various concentrations of inhibitors with or without 250 M of 8-Br-cAMP every 12 hours
for 48 hours. Control cells had medium changed every 12 hours. After 48 hours, cell
viability was recorded. BeWo cells were cultured in 6-well plates and treated with 10 M
of H-89 alone or in combination with 250 M 8-Br-cAMP for 48-hours. RT-qPCR was
then used to measure the effects of H-89 on (B) CGB3/5 expression, (C) LGALS13
expression, and (D) LGALS16 expression during trophoblastic differentiation. Cells treated
with H-89 showed no significant affect any of the genes tested during differentiation. Black
bars indicate untreated cells. Grey bars indicate cells treated with 8-Br-cAMP. Values are
presented as mean  SD (n=3). Significance is reported according to ***P < 0.001, *P <
0.05.
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